```
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *
 * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:07:43 ON 14 DEC 2009

=> file reg
=> Uploading C:\Program Files\Stnexp\Queries\Queries\10591174.str
```





```
chain nodes :
20  22  24  29  30
ring nodes :
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16
chain bonds :
2-24  3-22  9-20  10-14  12-30  16-29
ring bonds :
1-2  1-6  2-3  3-4  4-5  4-7  5-6  5-10  7-8  8-9  9-10  11-12  11-16  12-13  13-14
14-15  15-16
exact/norm bonds :
2-24  3-22  4-5  4-7  5-6  5-10  7-8  8-9  9-10  9-20  10-14  11-12  11-16  12-13
12-30  13-14  14-15  15-16  16-29
normalized bonds :
1-2  1-6  2-3  3-4
isolated ring systems :
containing 11 :


G1:C,H

G2:C,H,O,S,X

G3:C,O,S

G4:C,N

G5:C,O,X

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  20:CLASS  22:CLASS  24:CLASS
29:CLASS  30:CLASS

=> s l1 sam
L2            3 SEA SSS SAM L1
```

```
=> s l1 full
L3          574 SEA SSS FUL L1

=> file caplus

=> s l3
L4           75 L3

=> s l4 and pd< march 2004
      24855791 PD< MARCH 2004
                 (PD<20040300)
L5           61 L4 AND PD< MARCH 2004

=> dis l5 1-61 bib abs hitstr

L5   ANSWER 1 OF 61  CAPLUS  COPYRIGHT 2009 ACS on STN
AN   2004:1079594  CAPLUS  Full-text
DN   143:70979
TI   The chromatographic data in QSAR assay of TIQs derivatives with
     β2-adrenergic activity
AU   Brzezinska, Elzbieta; Stolarska, Justyna
CS   Department of Analytical Chemistry, Medical University of Lodz, Lodz,
     90-151, Pol.
SO   Acta Poloniae Pharmaceutica (2004), 61(4), 249-254
     CODEN: APPHAX; ISSN: 0001-6837
PB   Polish Pharmaceutical Society
DT   Journal
LA   English
AB   We performed QSAR anal. of β2-adrenergic activity and chromatog. data of
     4,6,8-trihydroxy-, 6,7-dihydroxy- and 6,7-dimethoxy-1,2,3,4-
     tetrahydroisoquinoline derivs.  TLC plates (silica gel NP 60 F254 and silica
     gel RP2 60F254 silanised precoated), impregnated with solns. of analogs of the
     selected amino acids were used as β2-agonistic and antagonistic interaction
     models.  QSAR anal. of the β2-adrenergic activity and the chromatog. data of
     the solutes were made.  A correlation between biol. data and behavior of the
     examined compds. in a chromatog. modifiable environment (S1-S3) was
     investigated by the linear regression anal. method.
IT   33033-84-0   188553-85-7
     RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic
     use); BIOL (Biological study); USES (Uses)
        (chromatog. data in QSAR assay of
        6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivs. with
        β2-adrenergic activity)
RN   33033-84-0  CAPLUS
CN   Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-1-(3,4,5-trimethoxyphenyl)-
       (CA INDEX NAME)
```



RN 188553-85-7 CAPLUS
CN 6,7-Isoquinolinediol, 1,2,3,4-tetrahydro-1-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:571544 CAPLUS Full-text
DN 141:296185
TI Asymmetric Pictet-Spengler reactions. Synthesis of tetrahydroisoquinoline derivatives from L-DOPA
AU Wang, Ye; Liu, Zhan Zhu; Chen, Shi Zhi; Liang, Xiao Tian
CS Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, 100050, Peop. Rep. China
SO Chinese Chemical Letters (2004), 15(5), 505-507
CODEN: CCLEE7; ISSN: 1001-8417
PB Chinese Chemical Society
DT Journal
LA English
OS CASREACT 141:296185
AB The cis-1-substituted-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid esters can be obtained in a highly diastereoselective fashion through 1,3-induction Pictet-Spengler cyclization of the L-DOPA (3,4-dihydroxyphenylalanine) Me ester with aromatic or aliphatic aldehydes under acidic conditions. Their epimers are also obtained as minor products.
IT 764660-42-6P 764660-55-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(asym. Pictet-Spengler reactions for preparation of tetrahydroisoquinoline derivs. from 3,4-Dihydroxyphenylalanine Me ester and aldehydes)
RN 764660-42-6 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2,3,4-tetrahydro-6,7-dihydroxy-1-(3,4,5-trimethoxyphenyl)-, methyl ester, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 764660-55-1 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2,3,4-tetrahydro-6,7-dihydroxy-1-(3,4,5-trimethoxyphenyl)-, methyl ester, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



OSC.G 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:362287 CAPLUS Full-text
DN 141:360522
TI Cardiopulmonary effects of the novel neuromuscular blocking drug GW280430A (AV430A) in dogs
AU Heerdt, Paul M.; Kang, Richard; The', Andrew; Hashim, Mir; Mook, Robert J.; Savarese, John J.
CS Departments of Anesthesiology and Pharmacology, Weill Medical College of Cornell University, New York, NY, 10021, USA
SO Anesthesiology (2004), 100(4), 846-851
CODEN: ANESAV; ISSN: 0003-3022
PB Lippincott Williams & Wilkins
DT Journal
LA English
AB Background: This investigation determined the cardiopulmonary side effects of a novel nondepolarizing neuromuscular blocking drug with an ultrashort duration of action in anesthetized male beagles. Methods: The ED95 for GW280430A was first determined in four animals. These data were then used to guide bolus dosing in multiples of ED95 in six dogs instrumented for hemodynamic measurements as well as inspiratory pressure and pulmonary compliance. Cardiopulmonary data were compared before and after the conclusion of a 60- to 90-min GW280430A infusion and in response to subsequent incremental bolus dosing starting with 3.125 + ED95. An adverse response was regarded as an alteration of 10% or greater in any variable. Arterial blood was obtained for histamine anal. before and 1 min after each dose. Results: The ED95 of GW280430A was 0.064 ± 0.01 mg/kg, and stable neuromuscular blockade was maintained with infusion of 0.012 ± 0.002 mg · kg-1 · min-1. With the exception of a late 14% increase in heart rate, there were no cardiopulmonary changes during infusion. Bolus dosing produced no cardiopulmonary change until a decrease in mean arterial pressure was elicited in four of six dogs at 25 + ED95. This response was modest, transient, and associated with a concomitant increase in plasma histamine concentration There were no accompanying changes indicative of direct myocardial depression, pulmonary vasoconstriction, or bronchospasm. Conclusions: These data indicate

that GW280430 does not produce demonstrable cardiovascular effects in the anesthetized dog until doses far in excess of the ED95 are administered as a bolus.

IT 213998-46-8, AV 4430A
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(AV 4430A, AV430A; GW280430A does not produce demonstrable cardiovascular effects in anesthetized dog until dose far greater than ED95 administered as rapid i.v. bolus)

RN 213998-46-0 CAPLUS

CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl-

PAGE 1-B



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:362286 CAPLUS Full-text
DN 141:360521
TI Preclinical pharmacology of GW280430A (AV430A) in the rhesus monkey and in the cat. A comparison with mivacurium
AU Savarese, John J.; Belmont, Matthew R.; Hashim, Mir A.; Mook, Robert A.; Boros, Eric E.; Samano, Vicente; Patel, Sanjay S.; Feldman, Paul L.; Schultz, Jan-Ake I.; McNulty, Michael; Spitzer, Timothy; Cohn, Douglas L.; Morgan, Philip; Wastila, William B.
CS Department of Anesthesiology, Weill Medical College of Cornell University and New York-Presbyterian Hospital, New York, NY, 10021, USA
SO Anesthesiology (2004), 100(4), 835-845
CODEN: ANESAV; ISSN: 0003-3022
PB Lippincott Williams & Wilkins
DT Journal
LA English
AB Background: No replacement for succinylcholine is yet available. GW280430A (AV430A) is a representative of a new class of nondepolarizing neuromuscular blocking drugs called asym. mixed-onium chlorofumarates. It undergoes rapid degradation in plasma by chemical hydrolysis and inactivation by cysteine adduction, resulting in a very short duration of effect. The neuromuscular, cardiovascular, and autonomic pharmacol. of GW280430A is compared herein with that of mivacurium. Methods: Adult male rhesus monkeys and adult male cats were anesthetized with nitrous oxide-oxygen-halothane and chloralose-pentobarbital, resp. The neuromuscular blocking properties of GW280430A and mivacurium were compared at a stimulation rate of 0.15 Hz in the extensor digitorum of the foot (monkey) and the tibialis anterior (cat). Sympathetic responses were assayed in the cat in the nictitating membrane preparation, and vagal effects were evaluated in the cat via observation of bradycardic responses after stimulation of the cervical right vagus nerve. Results: GW280430A and mivacurium were equipotent in the monkey (ED95 was 0.06 mg/kg in each case). GW280430A was half as potent as mivacurium in the cat. The total duration of action of GW280430A was less than half that of mivacurium in the monkey; recovery slopes were more than twice as rapid. The 25-75% recovery index of GW280430A did not vary significantly after various bolus doses or infusions, averaging 1.4-1.8 min in the monkey, significantly shorter than the same time interval (4.8-5.7 min) for mivacurium. Dose ratios for autonomic vs. neuromuscular blocking properties in the cat were greater than 25 for both GW280430A and mivacurium. The ratio ED Hist:ED95 Neuromuscular Block in the monkey was significantly greater (approx. 53 vs. 13) for GW280430A, indicating approx. four times less relative prominence of the side effects of skin flushing and decrease of blood pressure, which are associated with release of histamine. Conclusions: These expts. show a much shorter neuromuscular blocking effect and much-reduced side effects in the case of GW280430A vis-a-vis mivacurium. These results, together with the novel chemical degradation of GW280430A, suggest further evaluation in human subjects.
IT 213998-46-0, GW280430A
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(AV430A; GW280430A showed much shorter neuromuscular blocking effect and reduced side effects in anesthetized rhesus monkey, cat and chemical degradation, cardiovascular response compared with mivacurium suggest further evaluation in human subject)
RN 213998-46-0 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



OSC.G 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:362280 CAPLUS Full-text
DN 141:343098
TI Clinical pharmacology of GW280430A in humans
AU Belmont, Matthew R.; Lien, Cynthia A.; Tjan, Joseph; Bradley, Eleanor; Stein, Brenna; Patel, Sanjay S.; Savarese, John J.
CS Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY, 10021, USA
SO Anesthesiology (2004), 100(4), 768-773
CODEN: ANESAV; ISSN: 0003-3022
PB Lippincott Williams & Wilkins
DT Journal
LA English
AB Background: An ultrashort-acting nondepolarizing neuromuscular blocking agent that could be an alternative to succinylcholine has been the focus of a concerted effort in the field of muscle relaxants. GW280430A showed a

promising pharmacodynamic profile in preclin. work and a wide margin of safety and so was selected for study in humans. Methods: Thirty-one volunteers participated in this study, which determined the dose producing 95% block (ED95) and the safety and pharmacodynamics of increasing ED95 multiples. Anesthesia was induced and maintained with propofol, midazolam, and fentanyl. Neuromuscular transmission was measured at the adductor pollicis using ulnar nerve stimulation, and responses were recorded continuously by standard mechanomyog. monitoring. Results: The ED95 for GW280430A is 0.19 mg/kg. The time to onset of 90% block ranged from 1.3 to 2.1 min, depending on the dose. Clin. durations ranged from 4.7 to 10.1 min and increased with increasing dose. Five to 95% and 25-75% recovery rates were approx. 7 and 3 min, resp., and were independent of the dose administered. Transient cardiovascular side effects were observed at doses beginning at 3 + ED95 and above and were suggestive of histamine release. Most volunteers receiving 4 + ED95 exhibited plasma histamine concns. indicative of significant histamine release. Conclusions: GW280430A has a rapid onset and ultrashort duration of action. The recovery rate is rapid, predictable, and independent of dose. Doses at least up to 2.5 + ED95 seem to be free of side effects and seem to be able to provide relaxation within 60-90 s.

IT 213998-46-0, GW280430A
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GW280430A had rapid onset and ultrashort duration of action, recovery rate was rapid, predictable and independent of dose and doses at least up to 2.5 x ED95 seemed to be free of side effect and provided relaxation within 60-90 s in human)

RN 213998-46-0 CAPLUS

CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl-



OSC.G 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)
RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:78855 CAPLUS Full-text
DN 140:350017
TI Synthesis and anticonvulsant properties of tetrahydroisoquinoline derivatives
AU Gitto, Rosaria; Caruso, Roberta; Orlando, Valerie; Quartarone, Silvana; Barreca, Maria Letizia; Ferreri, Guido; Russo, Emilio; De Sarro, Giovambattista; Chimirri, Alba
CS Dipartimento Farmaco-Chimico, Universita di Messina, Messina, 98168, Italy
SO Farmaco (2004), 59(1), 7-12
CODEN: FRMCE8; ISSN: 0014-827X
PB Editions Scientifiques et Medicales Elsevier
DT Journal
LA English
OS CASREACT 140:350017
AB As a follow up of our previous structure-activity relationship and mol. modeling studies, we synthesized a novel series of 1-aryl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivs. as potential non-competitive AMPA receptor antagonists. When tested for their ability to prevent sound-induced seizures in DBA/2 mice, some of these novel compds. showed high anticonvulsant potency.
IT 682763-23-1P 682763-30-0P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and anticonvulsant properties of tetrahydroisoquinoline derivs. that act as non-competitive AMPA receptor antagonists)
RN 682763-23-1 CAPLUS
CN Isoquinoline, 1-(3,5-dichlorophenyl)-1,2,3,4-tetrahydro-6,7-dimethoxy- (CA INDEX NAME)



RN 682763-30-0 CAPLUS

CN Ethanone, 1-[1-(3,5-dichlorophenyl)-3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl]- (CA INDEX NAME)



OSC.G 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)
RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2003:347314 CAPLUS Full-text
DN 139:78440
TI Neuromuscular Blocking Activity and Therapeutic Potential of Mixed-Tetrahydroisoquinolinium Halofumarates and Halosuccinates in Rhesus Monkeys
AU Boros, Eric E.; Samano, Vicente; Ray, John A.; Thompson, James B.; Jung, David K.; Kaldor, Istvan; Koble, Cecilia S.; Martin, Michael T.; Styles, Virgil L.; Mook, Robert A., Jr.; Feldman, Paul L.; Savarese, John J.; Belmont, Matthew R.; Bigham, Eric C.; Boswell, G. Evan; Hashim, Mir A.; Patel, Sanjay S.; Wisowaty, James C.; Bowers, Gary D.; Moseley, Caroline L.; Walsh, John S.; Reese, Mindy J.; Rutkowske, Randy D.; Sefler, Andrea M.; Spitzer, Timothy D.
CS GlaxoSmithKline Research & Development, Research Triangle Park, NC, 27709, USA
SO Journal of Medicinal Chemistry (2003), 46(12), 2502-2515
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 139:78440
AB Structure-activity relationships in rhesus monkeys for a novel mixed-onium class of ultra-short-acting nondepolarizing tetrahydroisoquinolinium neuromuscular blockers (NMBs) are described. Bis-onium chlorofumarate 20a with (1R,2S)-benzyltetrahydroisoquinolinium groups was a potent lead compound (ED95 = 0.079 mg/kg) with an ultra-short duration of NMB effect (7.1 min) and a selectivity index (SI: defined as a ratio of the cardiovascular threshold dose to the ED95) similar to that of mivacurium. The mean threshold dose for cardiovascular effects with 20a was .apprx.20 times its ED95 value (SI = 20). A novel mixed-onium analog of was prepared by replacing the benzyltetrahydroisoquinolinium group distal to the fumarate chlorine atom with a (1S,2R)-phenyltetrahydroisoquinolinium moiety. The resulting mixed-onium chlorofumarate 24a displayed good NMB potency (ED95 = 0.063 mg/kg), ultra-short duration of action (5.6 min) and an improved selectivity index (SI = 57). Several other mixed-onium derivs. containing octanedioate (ED95 = 0.103 mg/kg), difluorosuccinate (ED95 = 0.056 mg/kg), and fluorofumarate (ED95 = 0.137 mg/kg) linkers were also potent, ultra-short-acting NMBs with good to excellent selectivity index values (SI = 37 - 96). Octanedioate was longer acting at higher doses compared to difluorosuccinate and chlorofumarate. Durations of NMB effect following a 0.4 mg/kg bolus dose (100% block) of octanedioate,difluorosuccinate , fluorofumarate and were 16.9, 13.0, and 10.0 min, resp. Recovery time for mixed-onium chlorofumarate following a 1 h

continuous infusion at 10 - 20 μg/kg/min (95 - 100% block) was .apprx.5 min which is similar to that observed following a 0.2 mg/kg bolus dose of this compound and indicates a lack of cumulative effects. Preliminary studies with chlorofumarate in whole human blood revealed that mixed-onium thiazolidine was the major metabolite and that plasma cholinesterases do not play the primary role in duration of NMB effect. The NMB properties of chlorofumarate in rhesus monkeys led to its clin. evaluation as a possible alternative to succinylcholine.

IT 213998-54-0P 213998-59-5P 213998-64-2P
213998-65-3P 213998-67-5P 213998-69-7P
213998-71-1P 213998-81-3P 213998-82-4P
213998-83-5P 213998-84-6P 213999-26-9P
213999-39-4P 213999-50-9P 213999-51-0P
213999-52-1P 347384-95-6P 552319-33-2P
552319-34-3P 552319-36-5P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(neuromuscular blocking activity and therapeutic potential of mixed-tetrahydroisoquinolinium halofumarates and halosuccinates in rhesus monkeys)

RN 213998-54-0 CAPLUS

CN Isoquinolinium, 2,2'-[[(2Z)-2-chloro-1,4-dioxo-2-butene-1,4-diyl]bis(oxy-3,1-propanediyl)]bis[1,2,3,4-tetrahydro-6,7,8-trimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, dichloride, (1R,1'R,2S,2'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl-

PAGE 1-B



RN 213998-59-5 CAPLUS
CN Isoquinolinium, 2-[3-[[1,8-dioxo-8-[3-[(1R,2S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]octyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



●2 Cl-

PAGE 1-B



RN 213998-64-2 CAPLUS
CN Isoquinolinium, 2-[3-[[1,8-dioxo-8-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]octyl]oxy]propyl]-1,2,3,4-

tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 213998-65-3 CAPLUS

CN Isoquinolinium, 2-[3-[[1,9-dioxo-9-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]nonyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



●2 Cl-

PAGE 1-B



RN 213998-67-5 CAPLUS
CN Isoquinolinium, 2-[3-[[1,6-dioxo-6-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]hexyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



●2 Cl-

PAGE 1-B



RN 213998-69-7 CAPLUS
CN Isoquinolinium, 2-[3-[[1,7-dioxo-7-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]heptyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 213998-71-1 CAPLUS
CN Isoquinolinium, 2-[3-[[1,10-dioxo-10-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-

dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]decyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



●2 Cl-

PAGE 1-B



RN 213998-81-3 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-3-chloro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinium-2-yl]propoxy]-2-buten-1-yl]oxy]propyl]-1,2,3,4-tetrahydro-6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 213998-82-4 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinium-2-yl]propoxy]-2-buten-1-yl]oxy]propyl]-1,2,3,4-tetrahydro-6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)-(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl−

PAGE 1-B



RN 213998-83-5 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-3-chloro-1,4-dioxo-4-[3-[(1R,2S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinium-2-yl]propoxy]-2-buten-1-yl]oxy]propyl]-1,2,3,4-tetrahydro-6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)-(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl−

PAGE 1-B



RN 213998-84-6 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-1,4-dioxo-4-[3-[(1R,2S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinium-2-yl]propoxy]-2-buten-1-yl]oxy]propyl]-1,2,3,4-tetrahydro-6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)-(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl-

PAGE 1-B



RN 213999-26-9 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-4-[3-[(1S)-3,4-dihydro-6,7-dimethoxy-1-(3,4,5-trimethoxyphenyl)-2(1H)-isoquinolinyl]propoxy]-1,4-dioxo-2-buten-1-yl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride, hydrochloride (1:1:1), (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 213999-39-4 CAPLUS
CN Isoquinolinium, 2-[3-[2,2-difluoro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]butoxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 213999-50-9 CAPLUS
CN Isoquinolinium, 2-[3-[2,2-difluoro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinium-2-yl]propoxy]butoxy]propyl]-1,2,3,4-tetrahydro-6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 213999-51-0 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-fluoro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl−

PAGE 1-B



RN 213999-52-1 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-fluoro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinium-2-yl]propoxy]-2-buten-1-yl]oxy]propyl]-1,2,3,4-tetrahydro-6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)-(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl−

PAGE 1-B



RN 347384-95-6 CAPLUS
CN 6H-Dibenzo[a,g]quinolizinium, 7-[3-[[(2Z)-2-chloro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-5,8,13,13a-tetrahydro-1,2,3,9,10,11-hexamethoxy-, dichloride, (7S,13aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 2-A

●2 Cl⁻

RN 552319-33-2 CAPLUS
CN Isoquinolinium, 2-[3-[(2S)-2-fluoro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]butoxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



●2 Cl⁻

PAGE 1-B



RN 552319-34-3 CAPLUS
CN Isoquinolinium, 2-[3-[[2,2-difluoro-1,5-dioxo-5-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]pentyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● 2 Cl⁻

PAGE 1-B



RN 552319-36-5 CAPLUS
CN Isoquinolinium, 2-[3-[3,3-difluoro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-

trimethoxyphenyl)isoquinolinio]propoxy]butoxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT 213998-45-9P 213998-46-0P 213998-47-1P
213998-48-2P 213998-53-9P 213998-57-3P
213998-58-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(neuromuscular blocking activity and therapeutic potential of mixed-tetrahydroisoquinolinium halofumarates and halosuccinates in rhesus monkeys)

RN 213998-45-9 CAPLUS

CN Isoquinolinium, 2-[3-[[(2Z)-3-chloro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



●2 Cl-

PAGE 1-B



RN 213998-46-0 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl−

PAGE 1-B



RN 213998-47-1 CAPLUS
CN Isoquinolinium, 2,2'-[[(2Z)-2-chloro-1,4-dioxo-2-butene-1,4-diyl]bis(oxy-3,1-propanediyl)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, dichloride, (1R,1'R,2S,2'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 213998-48-2 CAPLUS
CN Isoquinolinium, 2,2'-[[(2E)-1,4-dioxo-2-butene-1,4-diyl]bis(oxy-3,1-propanediyl)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, dichloride, (1R,1'R,2S,2'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 213998-53-9 CAPLUS
CN Isoquinolinium, 2,2'-[[(2Z)-2-chloro-1,4-dioxo-2-butene-1,4-diyl]bis(oxy-3,1-propanediyl)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, dichloride, (1S,1'S,2R,2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 213998-57-3 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-3-chloro-1,4-dioxo-4-[3-[(1R,2S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl−

PAGE 1-B



RN 213998-58-4 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-1,4-dioxo-4-[3-[(1R,2S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl-

PAGE 1-B



IT 198401-05-7P 220408-26-4P 552319-26-3P
552319-28-5P 552319-32-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(neuromuscular blocking activity and therapeutic potential of mixed-tetrahydroisoquinolinium halofumarates and halosuccinates in rhesus monkeys)
RN 198401-05-7 CAPLUS
CN Isoquinolinium, 1,2,3,4-tetrahydro-2-(3-hydroxypropyl)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, chloride (1:1), (1R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 220408-26-4 CAPLUS
CN Isoquinolinium, 1,2,3,4-tetrahydro-2-(3-hydroxypropyl)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, chloride (1:1), (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 552319-26-3 CAPLUS
CN Isoquinolinium, 1,2,3,4-tetrahydro-2-(3-hydroxypropyl)-6,7,8-trimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, chloride (1:1), (1R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 552319-28-5 CAPLUS
CN Isoquinolinium, 1,2,3,4-tetrahydro-2-(3-hydroxypropyl)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, chloride (1:1), (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 552319-32-1 CAPLUS
CN 2(1H)-Isoquinolinepropanol, 3,4-dihydro-6,7-dimethoxy-1-(3,4,5-trimethoxyphenyl)-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)
RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2003:281089 CAPLUS Full-text
DN 139:180218
TI A one-pot synthesis of (±) cryptostylines
AU Ruchirawat, Somsak; Bhavakul, Vanida; Chaisupakitsin, Malinee
CS Chulabhorn Research Institute, Bangkok, 10210, Thailand
SO Synthetic Communications (2003), 33(4), 621-625
CODEN: SYNCAV; ISSN: 0039-7911
PB Marcel Dekker, Inc.
DT Journal
LA English
OS CASREACT 139:180218
GI



I

AB A one-pot synthesis of cryptostylines I (R1 = H, OMe; R2, R3 = Me; R2-R3 = CH2) via the Pictet-Spengler reaction is reported.

IT 22324-83-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(one-pot preparation of (±) cryptostyline alkaloids from homoveratrylamine and aromatic aldehydes via Pictet-Spengler reaction and N-methylation with formaldehyde)

RN 22324-83-0 CAPLUS

CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2002:704029 CAPLUS Full-text

DN 138:231172

TI The pharmacoology of GW280430A: a new nondepolarizing neuromuscular blocking agent

AU Lien, Cynthia A.

CS Department of Anesthesiology, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY, USA

SO Seminars in Anesthesia, Perioperative Medicine and Pain (2002), 21(2), 86-91
CODEN: SAPPFJ

PB W. B. Saunders Co.

DT Journal; General Review

LA English

AB A review. GW280430A is a new nondepolarizing neuromuscular blocking agent, which is different from any other used either currently or in the past. It is a potent nondepolarizing agent that has a rapid onset of effect comparable in early volunteer trials to that of succinylcholine. Its unique chemical structure is responsible not only for its potency and nondepolarizing

neuromuscular blocking activity but also for its means of elimination from the plasma. Although other relaxants, such as mivacurium, undergo hydrolysis by plasma esterases, no other compound undergoes chemical hydrolysis and cysteine adduction. These reactions happen extremely quickly and are likely responsible for the ultrashort duration of action of GW280430A. If the results of further trials of this compound in patients undergoing surgical procedures are similar to those of the earlier volunteer trials, GW280430A promises to be the nondepolarizing equivalent of succinylcholine. Its development may allow for greater safety with the use of nondepolarizing neuromuscular blocking agents. With its ultrashort duration of action, unacceptable levels of neuromuscular blockade after extubation of the trachea and all associated adverse sequelae, such as decreased hypoxic drive to breathe, respiratory failure, and increased incidence of aspiration, may become things of the past.

IT 213998-46-0, GW 280430A
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. of new nondepolarizing neuromuscular blocking agent GW280430A in laboratory animals and humans)

RN 213998-46-0 CAPLUS

CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl−



OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2002:226386 CAPLUS Full-text
DN 137:299691
TI Preformulation studies for an ultrashort-acting neuromuscular blocking agent GW280430A. I. Buffer and cosolvent effects on the solution stability
AU Zhu, Haijian; Meserve, Kathy; Floyd, Alison
CS GlaxoSmithKline Inc., Research Triangle Park, NC, 27709, USA
SO Drug Development and Industrial Pharmacy (2002), 28(2), 135-142
CODEN: DDIPD8; ISSN: 0363-9045
PB Marcel Dekker, Inc.
DT Journal
LA English
AB GW280430A is an ultrashort-acting neuromuscular blocking agent targeted at muscle relaxation to facilitate surgical intubation. The objective of this study was to study the buffer and cosolvent effects on the solution stability of GW280430A. The buffer catalytic effect was examined in citrate, malate, tartrate, and glycine by measuring the rate of degradation of GW280430A (0.2 mg/mL) at constant pH (3), ionic strength (0.15M), and various buffer concns. (0.01-0.05M). The temperature dependence of the buffer catalytic effect and the degradation of the GW280430A in cosolvent (ethanol, propylene glycol, polyethylene glycol 400, N,N-dimethylacetamide)/water mixts. were studied at 40, 50, and 60°. The loss of parent drug was monitored by reverse-phase HPLC. The degradation of GW280430A followed first-order kinetics in all buffer solns. Significant buffer-catalyzed hydrolysis of GW280430A was observed with citrate, tartrate, and malate buffers, but not in glycine-buffered solns. The activation energies in all buffered drug solns. ranged from 70 to 80 kJ/mol and decreased with increasing buffer concentration GW280430A degradation was primarily through ester hydrolysis and followed first-order kinetics in aqueous solns. In cosolvent/water mixts., new degradation products were observed, indicating a chemical reaction between GW280430A and cosolvents. The reaction activation energies in the cosolvent/water mixts. ranged 75-85 kJ/mol, with the longest t0.9 at 5° equal to approx. 12 mo and at 25° equal to 36 days. Consideration should be given to the incorporation of glycine or a low concentration of citrate, malate, or tartrate buffer in the parenteral formulation development of GW280430A. Cosolvents prolonged the predicted t0.9 for GW280430A in solution, but the enhancement was not significant enough to pursue a liquid formulation.
IT 213998-46-8, GW 280430A
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(buffer and cosolvent effects on solution stability of neuromuscular blocker GW280430A)

RN 213998-46-0 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl⁻

PAGE 1-B



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2002:115984 CAPLUS Full-text
DN 137:284090
TI Solid state characterization of an neuromuscular blocking agent-GW280430A
AU Zhu, Haijian; Sacchetti, Mark
CS GlaxoSmithKline Inc., Research Triangle Park, NC, 27709, USA
SO International Journal of Pharmaceutics (2002), 234(1-2), 19-23
CODEN: IJPHDE; ISSN: 0378-5173
PB Elsevier Science B.V.

DT Journal
LA English
AB GW280430A is an ultrashort-acting neuromuscular blocking agent and is targeted for muscle relaxation as part of the intubation surgical procedure. The objective of this study was to perform solid state characterization on GW280430A and to evaluate the relationship between water content and glass transition temperature (Tg). GW280430A was characterized by differential scanning calorimetry, thermogravimetric anal., powder x-ray diffraction (PXRD), microscopy and moisture sorption. The effect of water content on the Tg of GW280430A was evaluated by equilibrating the material over saturated salt solns. at a range of relative humidities (6.4-72.6%) and determining the Tg by DSC using hermetically sealed aluminum pans. GW280430A undergoes dehydration at 40°, glass transition at 130° and decomposition at 190° by DSC. By PXRD and moisture sorption, GW280430A is an amorphous material and deliquesces at about 70% RH at room temperature Water acts as a potent plasticizer for GW280430A and the Tg decreases significantly as the water content increases. No measurable decomposition of GW280430A was observed after 4 wk at 40°/75% RH.
IT 213998-46-0, GW 280430A
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solid state characterization of an neuromuscular blocking agent GW280430A)
RN 213998-46-0 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



2 Cl-



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2001:472522 CAPLUS Full-text
DN 135:66254
TI pharmaceutical formulations containing histamine releasers
IN Floyd, Alison G.; Hashim, Mir A.; Lin, Peiyuan; Mook, Robert A.; Sefler, Andrea
PA Glaxo Group Ltd., UK
SO PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001045741	A2	20010628	WO 2000-US33772	20001213 <--
	WO 2001045741	A3	20011206		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2394794	A1	20010628	CA 2000-2394794	20001213 <--
	CA 2394794	C	20090825		
	EP 1239884	A2	20020918	EP 2000-984305	20001213 <--
	EP 1239884	B1	20070411		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003518074	T	20030603	JP 2001-546680	20001213 <--
	AU 779889	B2	20050217	AU 2001-20945	20001213
	AT 359092	T	20070515	AT 2000-984305	20001213
	ES 2284548	T3	20071116	ES 2000-984305	20001213
	US 20030096839	A1	20030522	US 2002-149722	20020613 <--
	US 6911455	B2	20050628		
	MX 2002006266	A	20021205	MX 2002-6266	20020621 <--
PRAI	US 1999-171696P	P	19991222		
	WO 2000-US33772	W	20001213		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention relates to pharmaceutical formulations and methods for preparing pharmaceutical formulations of histamine releasers. The present invention provides methods for determining the concentration of physiol. acceptable excipient for use in the formulations of invention. Methods for suppressing pharmaceutically-induced histamine release by administering the formulations to an animal are also provided. A kit useful for preparing pharmaceutical formulations of histamine releasers is also described. The percent inhibition of histamine release by formulations containing a tetrahydroisoquinoline derivative and citric acid, an excipient (12.5 mg/mL), at pH 3 was 90.8.

IT 213998-46-0

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical formulations containing histamine releasers)

RN 213998-46-0 CAPLUS

CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl-

PAGE 1-B



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 13 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2001:290361 CAPLUS Full-text
DN 135:77006
TI Stereocontrolled Synthesis of cis-Dibenzoquinolizine Chlorofumarates: Curare-Like Agents of Ultrashort Duration
AU Kaldor, Istvan; Feldman, Paul L.; Mook, Robert A., Jr.; Ray, John A.; Samano, Vicente; Sefler, Andrea M.; Thompson, James B.; Travis, Benjamin R.; Boros, Eric E.
CS Division of Medicinal Chemistry, GlaxoSmithKline Research & Development, Research Triangle Park, NC, 27709, USA
SO Journal of Organic Chemistry (2001), 66(10), 3495-3501
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
OS CASREACT 135:77006
AB Cis-Dibenzoquinoliziniumpropanols were prepared stereoselectively and were transformation into bis- and mixed-onium chlorofumarates. The title compds. displayed curare-like effects of ultrashort duration in rhesus monkeys.
IT 213999-53-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(stereocontrolled synthesis of cis-dibenzoquinolizine chlorofumarates, curare-like agents of ultrashort duration)
RN 213999-53-2 CAPLUS
CN Isoquinolinium, 1,2,3,4-tetrahydro-2-(3-hydroxypropyl)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, chloride (1:1), (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 347384-95-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(stereocontrolled synthesis of cis-dibenzoquinolizine chlorofumarates, curare-like agents of ultrashort duration)
RN 347384-95-6 CAPLUS
CN 6H-Dibenzo[a,g]quinolizinium, 7-[3-[[(2Z)-2-chloro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-5,8,13,13a-tetrahydro-1,2,3,9,10,11-hexamethoxy-, dichloride, (7S,13aR)-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 2-A

OSC.G 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)
RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 14 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2000:553442 CAPLUS Full-text
DN 133:168383
TI Pharmaceutical compositions containing nicotine or a ligand of nicotine receptors and a monamine oxidase inhibitor and their use for treating tobacco withdrawal symptoms
IN Caille, Dominique; George, Pascal; Jegham, Samir; Robineau, Pascale; Scatton, Bernard; Zivkovic, Branimir
PA Sanofi-Synthelabo, Fr.
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000045846	A1	20000810	WO 2000-FR193	20000128 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

FR 2788982	A1	20000804	FR 1999-1144	19990202	<--
FR 2788982	B1	20020802			
CA 2361437	A1	20000810	CA 2000-2361437	20000128	<--
EP 1150715	A1	20011107	EP 2000-901660	20000128	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
HU 2002001279	A2	20020928	HU 2002-1279	20000128	<--
JP 2002536342	T	20021029	JP 2000-596965	20000128	<--
MX 2001007812	A	20020108	MX 2001-7812	20010802	<--
PRAI FR 1999-1144	A	19990202			
WO 2000-FR193	W	20000128			

OS MARPAT 133:168383

AB The invention concerns novel pharmaceutical compns. containing nicotine or a ligand of nicotine receptors and a monamine oxidase inhibitor designed for treating tobacco withdrawal symptoms. A bilayer tablet contained befloxatone 5, lactose 66, microcryst. cellulose 20, povidone 4, crospovidone 4, and magnesium stearate 1% in the first layer, and nicotine polarcrilex 5, microcryst. cellulose 20 povidone 4, hydroxypropyl Me cellulose 25, magnesium stearate 1, and lactose q.s. 100% in the second layer.

IT 213998-46-0, GW 280430

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical compns. containing nicotine or ligand of nicotine receptors and monamine oxidase inhibitor and their use for treating tobacco withdrawal symptoms)

RN 213998-46-0 CAPLUS

CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



●2 Cl−



OSC.G 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 15 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1999:757502 CAPLUS Full-text
DN 132:107858
TI Synthesis of Ultra-Short-Acting Neuromuscular Blocker GW 0430: A Remarkably Stereo- and Regioselective Synthesis of Mixed Tetrahydroisoquinolinium Chlorofumarates
AU Samano, Vicente; Ray, John A.; Thompson, James B.; Mook, Robert A. ,Jr.; Jung, David K.; Koble, Cecilia S.; Martin, Michael T.; Bigham, Eric C.; Regitz, Craig S.; Feldman, Paul L.; Boros, Eric E.
CS Department of Chemistry, Glaxo Wellcome Research and Development, Research Triangle Park, NC, 27709, USA
SO Organic Letters (1999), 1(12), 1993-1996
CODEN: ORLEF7; ISSN: 1523-7060
PB American Chemical Society
DT Journal
LA English
OS CASREACT 132:107858
AB The stereo- and regioselective synthesis of ultra-short-acting nondepolarizing neuromuscular blocker GW 0430 is described. Key steps involved the enantioselective transfer hydrogenation of an imine employing Noyori's catalyst, stereoselective crystallization and methanolysis of trans-betaines, and stereo- and regioselective trans elimination of hydrogen chloride. The latter transformation allowed complete control of the position of the chloro substituent and stereochem. at the double bond of the linker.
IT 213998-45-9P 213998-46-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(stereo- and regioselective preparation of mixed tetrahydroisoquinolinium chlorofumarates)
RN 213998-45-9 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-3-chloro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl−

PAGE 1-B



RN 213998-46-0 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl-

PAGE 1-B



IT 22325-16-2P 213999-53-2P 213999-54-3P
214191-39-8P 255821-84-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(stereo- and regioselective preparation of mixed tetrahydroisoquinolinium chlorofumarates)
RN 22325-16-2 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 213999-53-2 CAPLUS
CN Isoquinolinium, 1,2,3,4-tetrahydro-2-(3-hydroxypropyl)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, chloride (1:1), (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 213999-54-3 CAPLUS
CN Isoquinolinium, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-2-[3-(sulfooxy)propyl]-1-(3,4,5-trimethoxyphenyl)-, inner salt, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 214191-49-8 CAPLUS
CN Isoquinolinium, 1,2,3,4-tetrahydro-2-(3-hydroxypropyl)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, chloride (1:1), (1S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 255821-84-2 CAPLUS
CN Formic acid, compd. with (1S)-1,2,3,4-tetrahydro-6,7-dimethoxy-1-(3,4,5-trimethoxyphenyl)isoquinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 32886-69-4
CMF C20 H25 N O5

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

OSC.G 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)
RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 16 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1999:173738 CAPLUS Full-text
DN 130:281969
TI Bis- and Mixed-Tetrahydroisoquinolinium Chlorofumarates: New Ultra-Short-Acting Nondepolarizing Neuromuscular Blockers. [Erratum to

document cited in CA130:168224]

AU Boros, Eric E.; Bigham, Eric C.; Boswell, G. Evan; Mook, Robert A., Jr.; Patel, Sanjay S.; Savarese, John J.; Ray, John A.; Thompson, James B.; Hashim, Mir A.; Wisowaty, James C.; Feldman, Paul L.; Samano, Vicente

CS Glaxo Wellcome Research and Development, Research Triangle Park, NC, 27709, USA

SO Journal of Medicinal Chemistry (1999), 42(6), 1114
CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

AB On page 207, under Neuromuscular Pharmacol., sentence 1, line 3, "or" should be replaced with "and": Rhesus monkeys (adult males, 8-15 kg) were anesthetized with ketamine (5 mg/kg, i.m.) and sodium pentobarbital (205 mg/kg, iv).

IT 213998-45-9P 213998-46-0P 213998-47-1P
213998-48-2P 213998-53-9P 213998-57-3P
213998-58-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(bis- and mixed-tetrahydroisoquinolinium chlorofumarates as ultra-short-acting nondepolarizing neuromuscular blockers (Erratum))

RN 213998-45-9 CAPLUS

CN Isoquinolinium, 2-[3-[[(2Z)-3-chloro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 213998-46-0 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



2 Cl-

PAGE 1-B



RN 213998-47-1 CAPLUS
CN Isoquinolinium, 2,2'-[[(2Z)-2-chloro-1,4-dioxo-2-butene-1,4-diyl]bis(oxy-3,1-propanediyl)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, dichloride, (1R,1'R,2S,2'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



2 Cl-

PAGE 1-B



RN 213998-48-2 CAPLUS
CN Isoquinolinium, 2,2'-[[(2E)-1,4-dioxo-2-butene-1,4-diyl]bis(oxy-3,1-propanediyl)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, dichloride, (1R,1'R,2S,2'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 213998-53-9 CAPLUS
CN Isoquinolinium, 2,2'-[[(2Z)-2-chloro-1,4-dioxo-2-butene-1,4-diyl]bis(oxy-3,1-propanediyl)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, dichloride, (1S,1'S,2R,2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 213998-57-3 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-3-chloro-1,4-dioxo-4-[3-[(1R,2S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 213998-58-4 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-1,4-dioxo-4-[3-[(1R,2S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl-

PAGE 1-B



IT 213999-53-2 220408-26-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(bis- and mixed-tetrahydroisoquinolinium chlorofumarates as ultra-short-acting nondepolarizing neuromuscular blockers (Erratum))
RN 213999-53-2 CAPLUS
CN Isoquinolinium, 1,2,3,4-tetrahydro-2-(3-hydroxypropyl)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, chloride (1:1), (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 220408-26-4 CAPLUS
CN Isoquinolinium, 1,2,3,4-tetrahydro-2-(3-hydroxypropyl)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, chloride (1:1), (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L5 ANSWER 17 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1999:8655 CAPLUS Full-text
DN 130:168224
TI Bis- and Mixed-Tetrahydroisoquinolinium Chlorofumarates: New Ultra-Short-Acting Nondepolarizing Neuromuscular Blockers
AU Boros, Eric E.; Bigham, Eric C.; Boswell, G. Evan; Mook, Robert A., Jr.; Patel, Sanjay S.; Savarese, John J.; Ray, John A.; Thompson, James B.; Hashim, Mir A.; Wisowaty, James C.; Feldman, Paul L.; Samano, Vicente
CS Glaxo Wellcome Research and Development, Research Triangle Park, NC, 27709, USA
SO Journal of Medicinal Chemistry (1999), 42(2), 206-209
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. such as I (n = 0, 1; X = H, Cl) were prepared by reaction of the isoquinolinium headgroups with chlorofumaryl or fumaryl chloride in dichloroethane. Potency values (ED95), onset times, and duration of neuromuscular blocking action were measured in rhesus monkeys.

IT 213998-45-9P 213998-46-0P 213998-47-1P
213998-48-2P 213998-53-9P 213998-57-3P
213998-58-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(bis- and mixed-tetrahydroisoquinolinium chlorofumarates as ultra-short-acting nondepolarizing neuromuscular blockers)

RN 213998-45-9 CAPLUS

CN Isoquinolinium, 2-[3-[[(2Z)-3-chloro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



2 Cl−

PAGE 1-B



RN 213998-46-0 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl-

PAGE 1-B



RN 213998-47-1 CAPLUS
CN Isoquinolinium, 2,2'-[[(2Z)-2-chloro-1,4-dioxo-2-butene-1,4-diyl]bis(oxy-3,1-propanediyl)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, dichloride, (1R,1'R,2S,2'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 213998-48-2 CAPLUS
CN Isoquinolinium, 2,2'-[[(2E)-1,4-dioxo-2-butene-1,4-diyl]bis(oxy-3,1-propanediyl)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, dichloride, (1R,1'R,2S,2'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 213998-53-9 CAPLUS
CN Isoquinolinium, 2,2'-[[(2Z)-2-chloro-1,4-dioxo-2-butene-1,4-diyl]bis(oxy-3,1-propanediyl)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, dichloride, (1S,1'S,2R,2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 213998-57-3 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-3-chloro-1,4-dioxo-4-[3-[(1R,2S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 213998-58-4 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-1,4-dioxo-4-[3-[(1R,2S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl-

PAGE 1-B



IT 213999-53-2 220408-26-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(bis- and mixed-tetrahydroisoquinolinium chlorofumarates as ultra-short-acting nondepolarizing neuromuscular blockers)
RN 213999-53-2 CAPLUS
CN Isoquinolinium, 1,2,3,4-tetrahydro-2-(3-hydroxypropyl)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, chloride (1:1), (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 220408-26-4 CAPLUS
CN Isoquinolinium, 1,2,3,4-tetrahydro-2-(3-hydroxypropyl)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, chloride (1:1), (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 20 THERE ARE 20 CAPLUS RECORDS THAT CITE THIS RECORD (20 CITINGS)
RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 18 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1998:672522 CAPLUS Full-text
DN 129:275845
OREF 129:56249a
TI Substituted isoquinolines as ultra short acting neuromuscular blockers
IN Bigham, Eric Cleveland; Boswell, Grady Evan; Savarese, John Joseph; Swaringen, Roy Archibald, Jr.; Patel, Sanjay Shashikant; Boros, Eric Eugene; Mook, Robert Anthony, Jr.; Samano, Vincente
PA Glaxo Group Limited, UK; Cornell Research Foundation Inc.
SO PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9842675	A1	19981001	WO 1998-EP1652	19980323 <--

```
        W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
            DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG,
            KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
            NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
            UA, UG, US, UZ, VN, YU, ZW
        RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,
            FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,
            GA, GN, ML, MR, NE, SN, TD, TG
    AU 9867305          A     19981020    AU 1998-67305          19980323 <--
    ZA 9802452          A     19990923    ZA 1998-2452           19980323 <--
    EP 971898           A1    20000119    EP 1998-912494         19980323 <--
    EP 971898           B1    20050511
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO
    TR 9902330          T2    20000221    TR 1999-2330           19980323 <--
    JP 2002503220       T     20020129    JP 1998-543233         19980323 <--
    JP 4112016          B2    20080702
    EP 1380573          A2    20040114    EP 2003-20565          19980323 <--
    EP 1380573          A3    20040121
    EP 1380573          B1    20090506
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, LT, LV, FI, MK, AL, RO, SI
    ES 2210757          T3    20040701    ES 1998-922626         19980323
    CZ 293786           B6    20040714    CZ 1999-3404           19980323
    EP 1526130          A1    20050427    EP 2005-1475           19980323
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, AL
    AT 295351           T     20050515    AT 1998-912494         19980323
    CN 1203061          C     20050525    CN 1998-805300         19980323
    ES 2242275          T3    20051101    ES 1998-912494         19980323
    IN 1998CA00478      A     20051202    IN 1998-CA478          19980323
    AT 430734           T     20090515    AT 2003-20565          19980323
    HR 9800157          B1    20041031    HR 1998-157            19980324
    TW 505635           B     20021011    TW 1998-87106631       19980429 <--
    US 6177445          B1    20010123    US 1999-381721         19991222 <--
    JP 2008019272       A     20080131    JP 2007-247928         20070925
PRAI GB 1997-6117       A     19970325
    GB 1997-24987       A     19971127
    EP 1998-912494      A3    19980323
    EP 1998-922626      A3    19980323
    JP 1998-543233      A3    19980323
    WO 1998-EP1652      W     19980323
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS   MARPAT 129:275845
GI
```

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Ultra short acting neuromuscular blocking agents I [q, t = 0-4; X1, X2 = halo; ha, hb = 0-2; Z1, Z2 = H, C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl with the proviso that Z1 and Z2 are not both hydrogen; Y1, Y2, Y3, Y4 = H, halo, C1-3 alkoxy; m, p = 1-6; n, r = 0-4; with the proviso that if ha and hb are both 0, then r is 0 and n is 0 to 2; R1-R14 = H, halo, C1-3 alkoxy, or R2 and R3 together with the carbon atoms to which they are bonded, R5 and R6 together with the carbon atoms to which they are bonded, R9 and R10 together with the carbon atoms to which they are bonded, R12 and R13 together with the carbon atoms to which they are bonded, may independently form a methylenedioxy or

ethylenedioxy moiety contained in a five- or six-membered ring; W1, W2 = C; A is a pharmaceutically acceptable anion], which are useful as skeletal muscle relaxants during emergency intubation procedures, routine surgery and post-operative settings, are disclosed. E.g., (Z)-2-chloro-1-{3-[(1S,2R)-6,7-dimethoxy-2-methyl-1-(3,4,5- trimethoxyphenyl)-1,2,3,4-tetrahydro-2-isoquinolinio]propyl}-4-{3-((1R,2S)- 6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4- tetrahydro-2-isoquinolinio}propyl}-2-butenedioate dichloride was prepared

IT 213998-45-9P 213998-46-0P 213998-47-1P
213998-48-2P 213998-49-3P 213998-50-6P
213998-51-7P 213998-52-8P 213998-53-9P
213998-54-0P 213998-55-1P 213998-57-3P
213998-58-4P 213998-59-5P 213998-62-0P
213998-63-1P 213998-64-2P 213998-65-3P
213998-66-4P 213998-67-5P 213998-68-6P
213998-69-7P 213998-70-0P 213998-71-1P
213998-72-2P 213998-75-5P 213998-76-6P
213998-77-7P 213998-78-8P 213998-79-9P
213998-80-2P 213998-81-3P 213998-82-4P
213998-83-5P 213998-84-6P 213999-19-0P
213999-20-3P 213999-24-7P 213999-25-8P
213999-26-9P 213999-27-0P 213999-28-1P
213999-31-6P 213999-32-7P 213999-38-3P
213999-39-4P 213999-40-7P 213999-41-8P
213999-42-9P 213999-46-3P 213999-47-4P
213999-50-9P 213999-51-0P 213999-52-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted isoquinolines as ultra short acting neuromuscular blockers)

RN 213998-45-9 CAPLUS

CN Isoquinolinium, 2-[3-[[(2Z)-3-chloro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl−

PAGE 1-B



RN 213998-46-0 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl−

PAGE 1-B



RN 213998-47-1 CAPLUS
CN Isoquinolinium, 2,2'-[[(2Z)-2-chloro-1,4-dioxo-2-butene-1,4-diyl]bis(oxy-3,1-propanediyl)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, dichloride, (1R,1'R,2S,2'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 213998-48-2 CAPLUS
CN Isoquinolinium, 2,2'-[[(2E)-1,4-dioxo-2-butene-1,4-diyl]bis(oxy-3,1-

propanediyl)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, dichloride, (1R,1'R,2S,2'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



2 Cl-

PAGE 1-B



RN 213998-49-3 CAPLUS
CN Isoquinolinium, 2,2'-[(1,8-dioxo-1,8-octanediyl)bis(oxy-3,1-propanediyl)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, dichloride, (1R,1'R,2S,2'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



●2 Cl-

PAGE 1-B



RN 213998-50-6 CAPLUS
CN Isoquinolinium, 2,2'-[(1,8-dioxo-1,8-octanediyl)bis(oxy-3,1-propanediyl)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, dichloride, (1R,1'R,2R,2'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



●2 Cl-

PAGE 1-B



RN 213998-51-7 CAPLUS
CN Isoquinolinium, 2,2'-[(1,8-dioxo-1,8-octanediyl)bis(oxy-3,1-propanediyl)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, dichloride, (1S,1'S,2R,2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



2 Cl-

PAGE 1-B



RN 213998-52-8 CAPLUS
CN Isoquinolinium, 2,2'-[(1,8-dioxo-1,8-octanediyl)bis(oxy-3,1-propanediyl)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, dichloride, (1S,1'S,2R,2'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 213998-53-9 CAPLUS
CN Isoquinolinium, 2,2'-[[(2Z)-2-chloro-1,4-dioxo-2-butene-1,4-diyl]bis(oxy-3,1-propanediyl)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, dichloride, (1S,1'S,2R,2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 213998-54-0 CAPLUS
CN Isoquinolinium, 2,2'-[[(2Z)-2-chloro-1,4-dioxo-2-butene-1,4-diyl]bis(oxy-3,1-propanediyl)]bis[1,2,3,4-tetrahydro-6,7,8-trimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, dichloride, (1R,1'R,2S,2'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 213998-55-1 CAPLUS
CN Isoquinolinium, 2,2'-[[(2Z)-2-chloro-1,4-dioxo-2-butene-1,4-diyl]bis(oxy-3,1-propanediyl)]bis[1,2,3,4-tetrahydro-6,7,8-trimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, dichloride, (1S,1'S,2R,2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 213998-57-3 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-3-chloro-1,4-dioxo-4-[3-[(1R,2S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 213998-58-4 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-1,4-dioxo-4-[3-[(1R,2S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl-

PAGE 1-B



RN 213998-59-5 CAPLUS
CN Isoquinolinium, 2-[3-[[1,8-dioxo-8-[3-[(1R,2S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]octyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 213998-62-0 CAPLUS

CN Isoquinolinium, 1-[(3,4-dimethoxyphenyl)methyl]-2-[3-[[1,8-dioxo-8-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]octyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 213998-63-1 CAPLUS
CN Isoquinolinium, 1-[(3,4-dimethoxyphenyl)methyl]-2-[3-[[1,8-dioxo-8-[3-[(1S,2S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]octyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 213998-64-2 CAPLUS
CN Isoquinolinium, 2-[3-[[1,8-dioxo-8-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-

dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]octyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



●2 Cl-

PAGE 1-B



RN 213998-65-3 CAPLUS

CN Isoquinolinium, 2-[3-[[1,9-dioxo-9-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]nonyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



●2 Cl-

PAGE 1-B



RN 213998-66-4 CAPLUS
CN Isoquinolinium, 2-[3-[[1,9-dioxo-9-[3-[(1S,2S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]nonyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



●2 Cl-

PAGE 1-B



RN 213998-67-5 CAPLUS
CN Isoquinolinium, 2-[3-[[1,6-dioxo-6-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]hexyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 213998-68-6 CAPLUS
CN Isoquinolinium, 2-[3-[[1,6-dioxo-6-[3-[(1S,2S)-1,2,3,4-tetrahydro-6,7-

dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]hexyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



●2 Cl-

PAGE 1-B



RN 213998-69-7 CAPLUS

CN Isoquinolinium, 2-[3-[[1,7-dioxo-7-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]heptyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



●2 Cl-

PAGE 1-B



RN 213998-70-0 CAPLUS
CN Isoquinolinium, 2-[3-[[1,7-dioxo-7-[3-[(1S,2S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]heptyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



●2 Cl-

PAGE 1-B



RN 213998-71-1 CAPLUS
CN Isoquinolinium, 2-[3-[[1,10-dioxo-10-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]decyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 213998-72-2 CAPLUS
CN Isoquinolinium, 2-[3-[[1,10-dioxo-10-[3-[(1S,2S)-1,2,3,4-tetrahydro-6,7-

dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]decyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



●2 Cl-

PAGE 1-B



RN 213998-75-5 CAPLUS

CN Isoquinolinium, 2-[3-[[(2Z)-3-chloro-1,4-dioxo-4-[3-[(1R,2S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-(2-propenyl)-1-(3,4,5-trimethoxyphenyl)-, dichloride, (1S,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl−

PAGE 1-B



RN 213998-76-6 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-1,4-dioxo-4-[3-[(1R,2S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-(2-propenyl)-1-(3,4,5-trimethoxyphenyl)-, dichloride, (1S,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 213998-77-7 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-3-chloro-4-[3-[(1R,2R)-1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-1-methylisoquinolinio]propoxy]-1,4-dioxo-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, dichloride, (1S,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl-

PAGE 1-B



RN 213998-78-8 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-4-[3-[(1R,2R)-1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methylisoquinolinio]propoxy]-1,4-dioxo-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, dichloride, (1S,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 213998-79-9 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-3-chloro-4-[3-[(1R,2S)-1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-1-methylisoquinolinio]propoxy]-1,4-dioxo-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, dichloride, (1S,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 213998-80-2 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-4-[3-[(1R,2S)-1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methylisoquinolinio]propoxy]-1,4-dioxo-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, dichloride, (1S,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 213998-81-3 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-3-chloro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinium-2-yl]propoxy]-2-buten-1-yl]oxy]propyl]-1,2,3,4-tetrahydro-6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)-(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 213998-82-4 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinium-2-yl]propoxy]-2-buten-1-yl]oxy]propyl]-1,2,3,4-tetrahydro-6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)-(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl−

PAGE 1-B



RN 213998-83-5 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-3-chloro-1,4-dioxo-4-[3-[(1R,2S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinium-2-yl]propoxy]-2-buten-1-yl]oxy]propyl]-1,2,3,4-tetrahydro-6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)-(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 213998-84-6 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-1,4-dioxo-4-[3-[(1R,2S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinium-2-yl]propoxy]-2-buten-1-yl]oxy]propyl]-1,2,3,4-tetrahydro-6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)-(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl−

PAGE 1-B



RN 213999-19-0 CAPLUS
CN 1,3-Dioxolo[4,5-g]isoquinolinium, 6-[3-[[(2Z)-3-chloro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-buten-1-yl]oxy]propyl]-5,6,7,8-tetrahydro-6-methyl-5-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (5R,6S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 213999-20-3 CAPLUS
CN 1,3-Dioxolo[4,5-g]isoquinolinium, 6-[3-[[(2Z)-2-chloro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-buten-1-yl]oxy]propyl]-5,6,7,8-tetrahydro-6-methyl-5-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (5R,6S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 213999-24-7 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-1,4-dioxo-4-[3-[(1S,2S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl-

PAGE 1-B



RN 213999-25-8 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-3-chloro-1,4-dioxo-4-[3-[(1S,2S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 213999-26-9 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-4-[3-[(1S)-3,4-dihydro-6,7-dimethoxy-1-(3,4,5-trimethoxyphenyl)-2(1H)-isoquinolinyl]propoxy]-1,4-dioxo-2-buten-1-yl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride, hydrochloride (1:1:1), (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 213999-27-0 CAPLUS
CN Isoquinolinium, 2-[3-[[(2E)-1,4-dioxo-4-[3-[(1R,2S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 213999-28-1 CAPLUS
CN Isoquinolinium, 2-[3-[3-chloro-1,4-dioxo-4-[3-[(1R,2S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]butoxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



●2 Cl−

PAGE 1-B



RN 213999-31-6 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-4-[3-[(1S,2S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-1,4-dioxo-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl-

PAGE 1-B



RN 213999-32-7 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-4-[3-[(1S,2R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-1,4-dioxo-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl−

PAGE 1-B



RN 213999-38-3 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-bromo-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dibromide, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 213999-39-4 CAPLUS
CN Isoquinolinium, 2-[3-[2,2-difluoro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]butoxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 213999-40-7 CAPLUS
CN Isoquinolinium, 2-[3-[3,3-difluoro-1,4-dioxo-4-[3-[(1R,2S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]butoxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 213999-41-8 CAPLUS
CN Isoquinolinium, 2-[3-[3,3-difluoro-1,4-dioxo-4-[3-[(1R,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]butoxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 213999-42-9 CAPLUS
CN Isoquinolinium, 2-[3-[2,2-difluoro-1,4-dioxo-4-[3-[(1S,2S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]butoxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 213999-46-3 CAPLUS
CN Isoquinolinium, 2-[3-[2-fluoro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]butoxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



2 Cl−

PAGE 1-B



RN 213999-47-4 CAPLUS

CN Isoquinolinium, 2-[3-[2-fluoro-1,4-dioxo-4-[3-[(1S,2S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]butoxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



2 Cl-

PAGE 1-B



RN 213999-50-9 CAPLUS

CN Isoquinolinium, 2-[3-[2,2-difluoro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinium-2-yl]propoxy]butoxy]propyl]-1,2,3,4-tetrahydro-6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 213999-51-0 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-fluoro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl−

PAGE 1-B



RN 213999-52-1 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-fluoro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinium-2-yl]propoxy]-2-buten-1-yl]oxy]propyl]-1,2,3,4-tetrahydro-6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)-(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl-

PAGE 1-B



IT 22325-16-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of substituted isoquinolines as ultra short acting neuromuscular blockers)
RN 22325-16-2 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 213999-53-2P 213999-54-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted isoquinolines as ultra short acting neuromuscular blockers)

RN 213999-53-2 CAPLUS
CN Isoquinolinium, 1,2,3,4-tetrahydro-2-(3-hydroxypropyl)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, chloride (1:1), (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 213999-54-3 CAPLUS
CN Isoquinolinium, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-2-[3-(sulfooxy)propyl]-1-(3,4,5-trimethoxyphenyl)-, inner salt, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 19 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1998:672521 CAPLUS Full-text
DN 129:290071
OREF 129:59118h,59119a
TI Preparation of dimeric isoquinolines as ultra short acting neuromuscular blockers.
IN Bigham, Eric Cleveland; Boswell, Grady Evan; Savarese, John Joseph; Swaringen, Roy Archibald, Jr.; Patel, Sanjay Shashikant; Boros, Eric Eugene; Mook, Robert Anthony, Jr.; Samano, Vincente
PA Glaxo Group Limited, UK; Cornell Research Foundation Inc.

SO PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9842674	A1	19981001	WO 1998-EP1651	19980323	<--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW					
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
	CA 2284802	A1	19981001	CA 1998-2284802	19980323	<--
	CA 2284802	C	20090616			
	AU 9875210	A	19981020	AU 1998-75210	19980323	<--
	AU 745382	B2	20020321			
	ZA 9802452	A	19990923	ZA 1998-2452	19980323	<--
	EP 975599	A1	20000202	EP 1998-922626	19980323	<--
	EP 975599	B1	20031112			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
	TR 9902330	T2	20000221	TR 1999-2330	19980323	<--
	EE 9900424	A	20000417	EE 1999-424	19980323	<--
	EE 4113	B1	20030815			
	BR 9808422	A	20000523	BR 1998-8422	19980323	<--
	NZ 337797	A	20010330	NZ 1998-337797	19980323	<--
	HU 2000001556	A2	20010428	HU 2000-1556	19980323	<--
	HU 2000001556	A3	20020128			
	JP 2002517168	T	20020611	JP 1998-543232	19980323	<--
	JP 4112015	B2	20080702			
	AT 254107	T	20031115	AT 1998-922626	19980323	<--
	EP 1380573	A2	20040114	EP 2003-20565	19980323	<--
	EP 1380573	A3	20040121			
	EP 1380573	B1	20090506			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, LT, LV, FI, MK, AL, RO, SI					
	ES 2210757	T3	20040701	ES 1998-922626	19980323	
	CZ 293786	B6	20040714	CZ 1999-3404	19980323	
	EP 1526130	A1	20050427	EP 2005-1475	19980323	
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, AL					
	CN 1203061	C	20050525	CN 1998-805300	19980323	
	IL 131918	A	20050925	IL 1998-131918	19980323	
	ES 2242275	T3	20051101	ES 1998-912494	19980323	
	IN 1998CA00478	A	20051202	IN 1998-CA478	19980323	
	PL 190860	B1	20060228	PL 1998-335885	19980323	
	AP 1797	A	20071231	AP 1999-1658	19980323	
	AT 430734	T	20090515	AT 2003-20565	19980323	
	HR 9800157	B1	20041031	HR 1998-157	19980324	
	TW 505635	B	20021011	TW 1998-87106631	19980429	<--
	MX 9908725	A	20010507	MX 1999-8725	19990923	<--
	NO 9904680	A	19991124	NO 1999-4680	19990924	<--
	NO 314726	B1	20030512			
	US 6187789	B1	20010213	US 2000-381719	20000119	<--
	HK 1023342	A1	20040730	HK 2000-102447	20000425	
	JP 2008019272	A	20080131	JP 2007-247928	20070925	

PRAI GB 1997-6117 A 19970325
GB 1997-24987 A 19971127
EP 1998-912494 A3 19980323
EP 1998-922626 A3 19980323
JP 1998-543233 A3 19980323
WO 1998-EP1651 W 19980323
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 129:290071
GI



I

AB Title compds. (I; X = halo; n = 1, 2; Y = H, OMe; A = pharmaceutically acceptable anion), were prepared Thus, 2,2-difluoro-4-[3-[(1S,2R)-6,7-dimethoxy-2-methyl-1-(3,4,5- trimethoxyphenyl)-1,2,3,4-tetrahydro-2-isoquinolinio]propyl]-1-[3-[(1R,2S)- 2-methyl-6,7,8-trimethoxy-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4- tetrahydro-2-isoquinolinio]propyl]butanedioate dichloride showed ED95 = 0.035 mg/kg i.v. for blockage of evoked twitch response of the tibialis anterior muscle.

IT 213998-45-9P 213998-46-0P 213998-57-3P
213998-58-4P 213998-81-3P 213998-82-4P
213998-83-5P 213998-84-6P 213999-24-7P
213999-38-3P 213999-39-4P 213999-46-3P
213999-47-4P 213999-50-9P 213999-51-0P
213999-52-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of dimeric isoquinolines as ultra short acting neuromuscular blockers)

RN 213998-45-9 CAPLUS

CN Isoquinolinium, 2-[3-[[(2Z)-3-chloro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



2 Cl−

PAGE 1-B



RN 213998-46-0 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl−

PAGE 1-B



RN 213998-57-3 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-3-chloro-1,4-dioxo-4-[3-[(1R,2S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 213998-58-4 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-1,4-dioxo-4-[3-[(1R,2S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl−

PAGE 1-B



RN 213998-81-3 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-3-chloro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinium-2-yl]propoxy]-2-buten-1-yl]oxy]propyl]-1,2,3,4-tetrahydro-6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)-(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 213998-82-4 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinium-2-yl]propoxy]-2-buten-1-yl]oxy]propyl]-1,2,3,4-tetrahydro-6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)-(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl−

PAGE 1-B



RN 213998-83-5 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-3-chloro-1,4-dioxo-4-[3-[(1R,2S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinium-2-yl]propoxy]-2-buten-1-yl]oxy]propyl]-1,2,3,4-tetrahydro-6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)-(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 213998-84-6 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-1,4-dioxo-4-[3-[(1R,2S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinium-2-yl]propoxy]-2-buten-1-yl]oxy]propyl]-1,2,3,4-tetrahydro-6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)-(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl−

PAGE 1-B



RN 213999-24-7 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-1,4-dioxo-4-[3-[(1S,2S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl−

PAGE 1-B



RN 213999-38-3 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-bromo-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dibromide, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 213999-39-4 CAPLUS
CN Isoquinolinium, 2-[3-[2,2-difluoro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]butoxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 213999-46-3 CAPLUS
CN Isoquinolinium, 2-[3-[2-fluoro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]butoxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 213999-47-4 CAPLUS
CN Isoquinolinium, 2-[3-[2-fluoro-1,4-dioxo-4-[3-[(1S,2S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]butoxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 213999-50-9 CAPLUS
CN Isoquinolinium, 2-[3-[2,2-difluoro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinium-2-yl]propoxy]butoxy]propyl]-1,2,3,4-tetrahydro-6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 213999-51-0 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-fluoro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl-

PAGE 1-B



RN 213999-52-1 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-fluoro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinium-2-yl]propoxy]-2-buten-1-yl]oxy]propyl]-1,2,3,4-tetrahydro-6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)-(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl-

PAGE 1-B



IT 22325-16-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of dimeric isoquinolines as ultra short acting neuromuscular blockers)
RN 22325-16-2 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 213999-42-9P 213999-53-2P 213999-54-3P

C14191-49-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of dimeric isoquinolines as ultra short acting neuromuscular blockers)

RN 213999-42-9 CAPLUS
CN Isoquinolinium, 2-[3-[2,2-difluoro-1,4-dioxo-4-[3-[(1S,2S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]butoxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



2 Cl-

PAGE 1-B



RN 213999-53-2 CAPLUS
CN Isoquinolinium, 1,2,3,4-tetrahydro-2-(3-hydroxypropyl)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, chloride (1:1), (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 213999-54-3 CAPLUS
CN Isoquinolinium, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-2-[3-(sulfooxy)propyl]-1-(3,4,5-trimethoxyphenyl)-, inner salt, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 214191-49-8 CAPLUS
CN Isoquinolinium, 1,2,3,4-tetrahydro-2-(3-hydroxypropyl)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, chloride (1:1), (1S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 20 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1997:661349 CAPLUS Full-text
DN 127:341647
OREF 127:66922h,66923a
TI Neuromuscular blocking activity of cyclic and acyclic bis-quaternary ammonium analogs of mivacurium chloride in the cat
AU Patel, Sanjay S.; Maehr, R.; Savarese, John J.; Jackson, Mary M.; Wastila, William B.; Wisowaty, James C.
CS Chem. Dev. Lab., Burroughs Wellcome Co., Research Triangle Park, NC, 27709, USA
SO European Journal of Pharmaceutical Sciences (1997), 5(5), 253-266
CODEN: EPSCED; ISSN: 0928-0987
PB Elsevier
DT Journal
LA English
AB The purpose of this work was to identify a new ultra-short-acting neuromuscular blocking agent devoid of the potential to produce cardiovascular effects at ≥ED95 doses. Four new bis-quaternary mivacurium analogs that are acyclic with respect to the bis-isoquinolinium nuclei and seven new bis-quaternary mivacurium analogs that are derivs. of (E)-oct-4-enedioic acid, (E)-oct-2-enedioic acid, and (E)-oct-4-enedithioic acid, were synthesized and tested for neuromuscular blocking activity in the cat. In general, compared with mivacurium, the acyclic analogs were of much lower potency but showed a faster onset (time from injection to maximum neuromuscular block) and a much shorter duration of action (time from injection to 95% recovery) at approx. ED95 doses. However, these acyclic analogs had a considerably narrower safety margin (i.e., the ratio of doses that produce unwanted cardiovascular or autonomic effects to those that produce neuromuscular block) than mivacurium. The (E)-oct-4-enedioate and (E)-oct-4-enedithioate analogs showed a neuromuscular blocking profile similar to the acyclic analogs. The (E)-oct-2-enedioate isomer of mivacurium did not have any advantageous neuromuscular blocking properties over mivacurium and, in fact, elicited cardiovascular and autonomic effects at much lower multiples of ED95. Structural changes to mivacurium, however minor, to either the inter-onium chain or the onium centers (or both) result in compds. whose cardiovascular and autonomic safety profiles are highly compromised in return for the desirable rapid onset and brevity of neuromuscular blocking action at ≥ED95 doses. The intact isoquinolinium nucleus appears to confer a superior safety profile over that of an acyclic onium nucleus.
IT 198400-96-3P
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(neuromuscular blocking activity of cyclic and acyclic bis-quaternary ammonium analogs of mivacurium chloride)
RN 198400-96-3 CAPLUS
CN Isoquinolinium, 2,2'-[(1,8-dioxo-2-octene-1,8-diyl)bis(oxy-3,1-propanediyl)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, dichloride, [1α,2β[E(1'R*,2'S*)]]- (9CI)
(CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl-

PAGE 1-B



IT 33033-86-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(neuromuscular blocking activity of cyclic and acyclic bis-quaternary ammonium analogs of mivacurium chloride)
RN 33033-86-2 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 198401-05-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(neuromuscular blocking activity of cyclic and acyclic bis-quaternary

ammonium analogs of mivacurium chloride)
RN 198401-05-7 CAPLUS
CN Isoquinolinium, 1,2,3,4-tetrahydro-2-(3-hydroxypropyl)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, chloride (1:1), (1R)- (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 21 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1997:183784 CAPLUS Full-text
DN 126:233107
OREF 126:44929a,44932a
TI An application of TLC chromatographic data in QSAR assay of TIQs derivatives with β2-adrenergic activity. Part I.
AU Brzezinska, Elzbieta
CS Institute of Chemistry and Technology of Drugs, School of Medicine, Lodz, 90-151, Pol.
SO Acta Poloniae Pharmaceutica (1996), 53(5), 383-388
CODEN: APPHAX; ISSN: 0001-6837
PB Polish Pharmaceutical Society
DT Journal
LA English
AB A QSAR anal. of β2-adrenergic activity and chromatog. data of 4,6,8-trihydroxy-, 6,7-dihydroxy- and 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivs. were made. The TLC plates (silica gel 60 F254 silanized precoated), impregnated with solns. of selected amino acides mixts., were used as a β2-agonistic and antagonistic interaction models. The hydrophobicity data of examined compds. (π and Σf-values) were obtained and used in the QSAR assay. Using a linear regression anal., interrelations between chromatog. and biol. activity data were found.
IT 33033-84-0 189553-85-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(QSAR anal. of β2-adrenergic activity and chromatog. data of trihydroxy-, dihydroxy- and dimethoxy-tetrahydroisoquinoline derivs.)
RN 33033-84-0 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-1-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 188553-85-7 CAPLUS
CN 6,7-Isoquinolinediol, 1,2,3,4-tetrahydro-1-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L5 ANSWER 22 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1997:183781 CAPLUS Full-text
DN 126:287916
OREF 126:55561a,55564a
TI Synthesis and pharmacological properties of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivatives
AU Brzezinska, Elzbieta
CS Institute of Chemistry and Technology of Drugs, School of Medicine, Lodz, 90-151, Pol.
SO Acta Poloniae Pharmaceutica (1996), 53(5), 365-371
CODEN: APPHAX; ISSN: 0001-6837
PB Polish Pharmaceutical Society
DT Journal
LA English
AB Some selected 1-aryl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivs. were synthesized and evaluated as the β-adrenoceptor agents. Some of the compds. showed a weak agonistic or antagonistic activity on these receptors.
IT 33033-84-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and pharmacol. properties of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivs.)
RN 33033-84-0 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-1-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L5 ANSWER 23 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1996:376527 CAPLUS Full-text
DN 125:167761
OREF 125:31433a
TI Asymmetric synthesis. XLI. Totally stereoselective synthesis of 1,3-disubstituted tetrahydroisoquinolines via the CN(R,S) method
AU Gosmann, Grace; Guillaume, Dominique; Husson, Henri-Philippe
CS Lab. Chimie Therapeutique associe CNRS, Univ. R. Descartes, Paris, 75270, Fr.
SO Tetrahedron Letters (1996), 37(25), 4369-4372
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier
DT Journal
LA English
OS CASREACT 125:167761
GI



AB Optically active cis- or trans- 1,3-disubstituted tetrahydroisoquinolines 3-R- or 3S-I (R = Me, CH2Ph) can be prepared selectively from the same oxazolidine II. This latter is easily obtained from keto-acid III and (R)-(-)phenylglycinol.

IT 180072-45-1P 180072-48-4P 180072-49-5P
180072-50-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(stereoselective preparation of isoquinolines)

RN 180072-45-1 CAPLUS
CN 2(1H)-Isoquinolineethanol, 3,4-dihydro-6,7-dimethoxy-β-phenyl-1-(3,4,5-trimethoxyphenyl)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 180072-48-4 CAPLUS
CN 3-Isoquinolinecarbonitrile, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-[(1R)-1-phenyl-2-[(trimethylsilyl)oxy]ethyl]-1-(3,4,5-trimethoxyphenyl)-, (1S)-(CA INDEX NAME)



RN 180072-49-5 CAPLUS
CN 3-Isoquinolinecarbonitrile, 1,2,3,4-tetrahydro-6,7-dimethoxy-3-methyl-2-[(1R)-1-phenyl-2-[(trimethylsilyl)oxy]ethyl]-1-(3,4,5-trimethoxyphenyl)-, (1S)- (CA INDEX NAME)



RN 180072-50-8 CAPLUS
CN 3-Isoquinolinecarbonitrile, 1,2,3,4-tetrahydro-6,7-dimethoxy-3-

(phenylmethyl)-2-[(1R)-1-phenyl-2-[(trimethylsilyl)oxy]ethyl]-1-(3,4,5-trimethoxyphenyl)-, (1S)- (CA INDEX NAME)



IT 32886-69-4P 180072-46-2P 180072-47-3P
180187-56-8P 180187-57-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(stereoselective preparation of isoquinolines)
RN 32886-69-4 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-1-(3,4,5-trimethoxyphenyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 180072-46-2 CAPLUS
CN 2(1H)-Isoquinolineethanol, 3,4-dihydro-6,7-dimethoxy-3-methyl-β-phenyl-1-(3,4,5-trimethoxyphenyl)-, [1S-[1α,2(S*),3β]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 180072-47-3 CAPLUS
CN 2(1H)-Isoquinolineethanol, 3,4-dihydro-6,7-dimethoxy-β-phenyl-3-

(phenylmethyl)-1-(3,4,5-trimethoxyphenyl)-, [1S-[1α,2(S*),3β]]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 180187-56-8 CAPLUS
CN 2(1H)-Isoquinolineethanol, 3,4-dihydro-6,7-dimethoxy-3-methyl-β-phenyl-1-(3,4,5-trimethoxyphenyl)-, [1S-[1α,2(S*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 180187-57-9 CAPLUS
CN 2(1H)-Isoquinolineethanol, 3,4-dihydro-6,7-dimethoxy-β-phenyl-3-(phenylmethyl)-1-(3,4,5-trimethoxyphenyl)-,
[1S-[1α,2(S*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)

L5 ANSWER 24 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1996:365418 CAPLUS Full-text
DN 125:75373
OREF 125:14059a,14062a
TI Synthesis and pharmacological investigations of 1,2,3,4-tetrahydroisoquinoline derivatives
AU Brzezinska, E.; Venter, D.; Glinka, R.
CS Institute Chemistry Technology Drugs, Medical University Lodz, Lodz, 90-151, Pol.
SO Pharmazie (1996), 51(6), 397-399
CODEN: PHARAT; ISSN: 0031-7144
PB Govi-Verlag Pharmazeutischer Verlag
DT Journal
LA English
AB Selected 1-aryl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline derivs. were synthesized and evaluated to determination the role of the hydrophobic Ph group at C-1 on the activity of these derivs. at β-adrenoreceptors. All the tests show that the investigated compds. are not very active. The Ph group is a poor substituent for β-adrenomimetic activity, but the presence of the Ph substituent at position 1 appears to enable these mol. to act as antagonists at β-adrenoreceptors.
IT 57529-51-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetrahydroisoquinoline derivs. and aryl group effect on β-adrenoreceptors)
RN 57529-51-8 CAPLUS
CN 6,7-Isoquinolinediol, 1,2,3,4-tetrahydro-1-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

L5 ANSWER 25 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1996:60166 CAPLUS Full-text
DN 124:202678
OREF 124:37481a,37484a
TI Synthesis of 3,4-dihydroisoquinolines, 2-alkyl(acyl)-1(2H)-3,4-dihydroisoquinolinones, 2-alkyl-1(2H)-isoquinolinones and 1-alkyl-2(2H)-quinolinones by oxidation with potassium permanganate
AU Venkov, Atanas P.; Statkova-Abeghe, Stela M.
CS Dep. Chem., Univ. Plovdiv, Plovdiv, 4000, Bulg.
SO Tetrahedron (1996), 52(4), 1451-60
CODEN: TETRAB; ISSN: 0040-4020

PB Elsevier
DT Journal
LA English
OS CASREACT 124:202678
AB Synthesis of 3,4-dihydroisoquinolines, 2-alkyl- and 2-acyl-3,4-dihydro-1(2H)-isoquinolinones, 2-alkyl-1(2H)-isoquinolinones, N-alkyl-3,4-dihydro-2(2H)-quinolinones and N-alkyl-2(2H)-quinolinones by oxidation of 1,2,3,4-tetrahydroisoquinolines, N-alkyl (acyl)iminium salts of 3,4-dihydroisoquinolines and isoquinoline as well as of N-alkyl ammonium salts of tetrahydroquinoline and quinoline with potassium permanganate is described.
IT 174503-32-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis of 3,4-dihydroisoquinolines, 2-alkyl(acyl)-1(2H)-3,4-dihydroisoquinolinones, 2-alkyl-1(2H)-isoquinolinones and 1-alkyl-2(2H)-quinolinones by oxidation with potassium permanganate)
RN 174503-32-3 CAPLUS
CN Isoquinoline, 1-(3,5-dimethoxyphenyl)-1,2,3,4-tetrahydro-6,7-dimethoxy- (CA INDEX NAME)



OSC.G 26 THERE ARE 26 CAPLUS RECORDS THAT CITE THIS RECORD (26 CITINGS)

L5 ANSWER 26 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1995:447155 CAPLUS Full-text
DN 123:56331
OREF 123:10159a,10162a
TI Some observations on the enantio- and diastereo-selective synthesis of 1-substituted-1,2,3,4-tetrahydroisoquinolines
AU Nagarajan, K.; Chandrasekharan, J.; Rodrigues, P. J.
CS R and D Centre, Searle India Ltd., Thane, 400 601, India
SO Journal of the Indian Institute of Science (1994), 74(2), 247-55
CODEN: JIISAD; ISSN: 0019-4964
DT Journal
LA English
GI



I



II

AB Several approaches to the synthesis of optically active 1-aryl-1,2,3,4-tetrahydroisoquinoline alkaloids, cryptostylines from dihydroisoquinoline precursors have been tried. Redns. of the 1-aryldihydroisoquinolines as well as of their methiodides with yeast are unsuccessful. Reduction of the quaternary salts, e.g. I, with sodium tris-acyloxyborohydrides gives the tetrahydroisoquinoline alkaloids in unsatisfactory enantiomeric excess. (±)-Norcryptostyline is resolved with (-)- and (+)-tartaric acid into (-)S and (+)R enantiomers, which are converted to their camphorsulfonyl derivs. II. Reaction of camphorsulfonyl homoveratryl amine with piperonal affords a mixture of 1R-II and 1S-II in the ratio of 4:3, whereas camphorsulfonylation of (±)-norcryptostyline gives 1R-II much in excess of 1S-II (4:1).

IT 22325-16-2P, Cryptostyline III
RL: SPN (Synthetic preparation); PREP (Preparation)
(enantio- and diastereoselective synthesis of substituted tetrahydroisoquinolines)

RN 22325-16-2 CAPLUS

CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



OSC.G 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)

L5 ANSWER 27 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1992:426304 CAPLUS Full-text
DN 117:26304

OREF 117:4739a,4742a
TI 1,4,4a,10b-Tetrahydro-N,N-dimethyl-4-phenanthridinamines and 1,4,4a,5,6,10b-hexahydro-N,N-dimethyl-4-phenanthridinamines
AU Bobowski, George; West, Barbara; Omecinsky, Diana
CS Parke-Davis Pharm. Res. Div., Warner-Lambert Co., Ann Arbor, MI, 48105, USA
SO Journal of Heterocyclic Chemistry (1992), 29(1), 33-49
CODEN: JHTCAD; ISSN: 0022-152X
DT Journal
LA English
OS CASREACT 117:26304
GI


V


VI

AB Synthetic procedures to prepare the title compds. are described. Diels-Alder cycloaddn. of β-nitrostyrene derivs. to N,N-dimethyl-1,3-butadien-1-amine gave 5-aryl-N,N-dimethyl-6-nitro-2-cyclohexen-1-amines (I). Reduction of I with zinc in acetic acid gave the diamino derivs. II. Schotten-Baumann acylation of II gave amides III. Treatment of II with alkyl isocyanates gave the aminourea derivs. IV. Bischler-Napieralski cyclodehydration of III and IV gave 1,4,4a,10b-tetrahydrophenanthridinamines, e.g., V, and N6-alkyl-1,4,4a,10b-tetrahydro-N4,N4-dimethyl-4,6-phenanthridinediamines, resp. Condensation of diamines II with aryl aldehydes under azeotropic conditions gave imines, which on treatment with acids yielded 6-aryl-1,4,4a,5,6,10b-hexahydro-N,N-dimethyl-4-phenanthridinamines, e.g., VI. The stereochem. of these materials is assigned by NMR.
IT 141944-66-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 141944-66-3 CAPLUS
CN 4-Phenanthridinamine, 1,4,4a,5,6,10b-hexahydro-8,9-dimethoxy-N,N-dimethyl-6-(3,4,5-trimethoxyphenyl)-, (4α,4aα,6β,10bβ)- (9CI)
(CA INDEX NAME)

Relative stereochemistry.



OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

L5 ANSWER 28 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1992:214753 CAPLUS Full-text
DN 116:214753
OREF 116:36409a,36412a
TI Enantioselective synthesis of 1-substituted 1,2,3,4-tetrahydroisoquinoline alkaloids via asymmetric reduction
AU Cho, Byung Tae; Han, Cheol Kyu
CS Dep. Chem., Hallym Univ., Chunchon, 200-702, S. Korea
SO Bulletin of the Korean Chemical Society (1991), 12(5), 565-9
CODEN: BKCSDE; ISSN: 0253-2964
DT Journal
LA English
OS CASREACT 116:214753
GI



I

AB Enantioselective synthesis of 1-substituted tetrahydroisoquinoline alkaloids I (R = alkyl, aryl, aralkyl; R1 = H, Me) via asym. reduction of 1-substituted 3,4-dihydroisoquinolines and the corresponding iminium salts with the selected chiral hydride reagents, such as K glucoride Itsuno's reagent and Mosher's reagent were examined In these reactions, dihydroisoquinolines were not reduced by the hydride reagents, whereas the iminium salts were easily reduced under the same reaction conditions found in successful reduction of ketones. Thus, the reduction of 6,7-dimethoxy-3,4-dihydroisoquinolium iodide with the chiral reducing agents provided the product I (R = R1 = Me) with 52.3% ee, 18% ee, and 66.4% ee, resp.

IT 22325-16-2P 33033-86-2P
RL: RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(enantioselective synthesis of, via asym. reduction)

RN 22325-16-2 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 33033-86-2 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-

trimethoxyphenyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L5 ANSWER 29 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1992:151593 CAPLUS Full-text
DN 116:151593
OREF 116:25653a,25656a
TI Preparation of tetrahydroisoquinolines as intermediates for alkaloids
IN Takano, Seiichi; Suzuki, Masato; Ogasawara, Kuniro
PA Kawaken Fine Chemicals Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 3 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 03236375	A	19911022	JP 1990-30698	19900209 <--
PRAI JP 1990-30698		19900209		

OS CASREACT 116:151593; MARPAT 116:151593
GI



AB The title compds. I (R1 = aryl; R2 = H, alkyl, alkoxy; n = 1, 2), are prepared by treating aromatic imines II (R1, R2, n = same as I) with radical initiators and Bu3SnH in solvents. II [R1 = Ph, (R2)n = 4,5-dimethoxy], Bu3SnH, and AIBN in toluene were refluxed for 2 h to give 21.1% I [R1 = Ph, (R2)n = 6,7-dimethoxy].
IT 33033-84-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, by cyclization of benzylidene(bromophenyl)ethylamine)
RN 33033-84-0 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-1-(3,4,5-trimethoxyphenyl)-
(CA INDEX NAME)



L5 ANSWER 30 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1990:591122 CAPLUS Full-text
DN 113:191122
OREF 113:32349a,32352a
TI Substituted 1,4-dihydro-1-phenylisoquinolin-3(2H)-ones as inhibitors of cyclic nucleotide phosphodiesterases from dog heart
AU Georgiev, V. S.; Van Inwegen, R. G.; Carlson, P.
CS Rorer Cent. Res., Horsham, PA, 19044, USA
SO European Journal of Medicinal Chemistry (1990), 25(4), 375-8
CODEN: EJMCA5; ISSN: 0223-5234
DT Journal
LA English
OS CASREACT 113:191122
GI



I

AB Phenylisoquinolinone and -thione derivs. I [R = Ph, 3,4,5-(MeO)3C6H2; R1, R2 = H, MeO; X = O, S] were prepared and tested for their antiallergic activity. 1-Phenylisoquinoline derivs. also showed antiallergic activity.
IT 130042-78-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antiallergic activity of)
RN 130042-78-3 CAPLUS
CN 3(2H)-Isoquinolinone, 1,4-dihydro-6,7-dimethoxy-1-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



L5 ANSWER 31 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1990:497865 CAPLUS Full-text
DN 113:97865
OREF 113:16545a,16548a
TI Enantioselective synthesis of cryptostyline I, II and III via asymmetric reduction
AU Cho, Byung Tae; Han, Cheol Kyu
CS Dep. Chem., Hallym Univ., Chuncheon, 200-702, S. Korea
SO Bulletin of the Korean Chemical Society (1990), 11(1), 81-2
CODEN: BKCSDE; ISSN: 0253-2964
DT Journal
LA English
GI



I



II

AB The title compds. [(S)-I, R = H, R1R2 = OCH2O, R1 = R2 = MeO; R = R1 = R2 = MeO] were prepared by asym. reduction of the isoquinolinium salts II with K glucoride, Itsumo's reagent, and Maskerh's reagent.
IT 22325-16-2P, Cryptostyline III 33033-86-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 22325-16-2 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 33033-86-2 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L5 ANSWER 32 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1990:497864 CAPLUS Full-text
DN 113:97864
OREF 113:16545a,16548a
TI Synthesis of racemic cryptostylines I, II, and III by radical cyclization
AU Takano, Seiichi; Suzuki, Mahito; Kijima, Atsushi; Ogasawara, Kunio
CS Pharm. Inst., Tohoku Univ., Sendai, 980, Japan
SO Chemistry Letters (1990), (2), 315-16
CODEN: CMLTAG; ISSN: 0366-7022
DT Journal
LA English
OS CASREACT 113:97864
GI



I



II

AB Three 1-phenyl-1,2,3,4-tetrahydroisoquinoline alkaloids, cryptostylines I (I, R1R2 = OCH2O, R3 = H), II (I, R1 = R2 = MeO, R3 = H), and III (I, R1 = R2 = R3 = MeO) were synthesized in racemic forms via a aryl radical-initiated cyclization of imines II.

IT 33033-84-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and methylation of)

RN 33033-84-0 CAPLUS

CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-1-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



IT 22324-83-0P, (±)-Cryptostyline III
RL: RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of)
RN 22324-83-0 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



OSC.G 28 THERE ARE 28 CAPLUS RECORDS THAT CITE THIS RECORD (28 CITINGS)

L5 ANSWER 33 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1990:458769 CAPLUS Full-text
DN 113:58769
OREF 113:9931a,9934a
TI The synthesis of 4-desoxy-2-azapodophyllotoxins
AU Van der Eycken, J.; Bosmans, J. P.; Van Haver, D.; Vandewalle, M.; Hulkenberg, A.; Veerman, W.; Nieuwenhuizen, R.
CS Dep. Org. Chem., State Univ. Gent, Ghent, B-9000, Belg.
SO Tetrahedron Letters (1989), 30(29), 3873-6
CODEN: TELEAY; ISSN: 0040-4039
DT Journal
LA English
OS CASREACT 113:58769
GI



I

AB 4-Desoxy-2-azapodophyllotoxins I (n = 1, 2), tetrahydroisoquinoline analogs of podophyllotoxin, have been synthesized and evaluated for their antitumor activities.

IT 128049-96-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, with dibromoethane)

RN 128049-96-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2,3,4-tetrahydro-6,7-dihydroxy-1-(3,4,5-trimethoxyphenyl)-, methyl ester, (1S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)

L5 ANSWER 34 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1990:118803 CAPLUS Full-text

DN 112:118803

OREF 112:20131a,20134a

TI Preparation of oxazoloisoquinolines as anticancer agents

IN Tawara, Tetsuji; Ichanagi, Yukio; Yamagami, Keiji; Fujii, Akihiro

PA Yoshitomi Pharmaceutical Industries, Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 9 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 01199976	A	19890811	JP 1987-284890	19871110 <--
PRAI JP 1987-255755	A1	19871008		

OS MARPAT 112:118803

GI



I

AB The title compds. I (R1, R2 = OH, alkoxy, R1R2 may be alkylenedioxy; X, Y, Z = OH, alkoxy), which have low toxicity, are prepared Treatment of 15.0 g Me cis-2-benzyloxycarbonyl-6,7-dihydroxy-1-(3,4,5-trimethoxyphenyl)- 1,2,3,4-tetrahydroisoquinoline-3-carboxylate (preparation given) with CH2Br2, K2CO3, and CuO in DMF at 100-110° for 4 h gave 12.0 g Me cis-2-benzyloxycarbonyl-1-(3,4,5-trimethoxyphenyl)-6,7-methylenedioxy- 1,2,3,4-tetrahydroisoquinoline-3-carboxylate, which (3.4 g) was treated with LiBH4 in THF at 50-55° for 9 h to afford 1.8 g cis-I (R1R2 = OCH2O; X = 3-OMe, Y = 4-OMe, Z = 5-OMe) (II). Administration of II at 100 mg/kg/day i.p. for 5 days to P388 leukemia cell-bearing mice showed 210% T/C (treated group/control group) survival time, vs. 157%, for podophylotoxin at 25 mg/kg/day. II at 300 mg/kg (i.p.) or 1000 mg/kg (p.o.) exhibited no toxicity (no information on test animal), whereas podophylotoxin at 25 mg/kg was toxic.

IT 125445-07-0P 125445-08-1P 125445-09-2P
125445-10-5P 125445-13-8P 125445-14-9P
125445-15-0P 125456-07-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of oxazoloisoquinolines)

RN 125445-07-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2,3,4-tetrahydro-6,7-dihydroxy-1-(3,4,5-trimethoxyphenyl)-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 125445-08-1 CAPLUS

CN 2,3(1H)-Isoquinolinedicarboxylic acid, 3,4-dihydro-6,7-dihydroxy-1-(3,4,5-trimethoxyphenyl)-, 2-(phenylmethyl) ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 125445-09-2 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2,3,4-tetrahydro-6,7-dihydroxy-1-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 125445-10-5 CAPLUS
CN 2,3(1H)-Isoquinolinedicarboxylic acid, 3,4-dihydro-6,7-dihydroxy-1-(3,4,5-trimethoxyphenyl)-, 3-methyl 2-(phenylmethyl) ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 125445-13-8 CAPLUS
CN 2,3(1H)-Isoquinolinedicarboxylic acid, 3,4-dihydro-6,7-dimethoxy-1-(3,4,5-trimethoxyphenyl)-, 3-methyl 2-(phenylmethyl) ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 125445-14-9 CAPLUS
CN 2,3(1H)-Isoquinolinedicarboxylic acid,
3,4-dihydro-6,7-dimethoxy-1-(3,4,5-trimethoxyphenyl)-, 2-(phenylmethyl)
ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 125445-15-0 CAPLUS
CN 2,3(1H)-Isoquinolinedicarboxylic acid,
3,4-dihydro-6,7-dimethoxy-1-(3,4,5-trimethoxyphenyl)-, 3-methyl
2-(phenylmethyl) ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 125456-07-7 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid,
3,4-dihydro-6,7-dihydroxy-3-(hydroxymethyl)-1-(3,4,5-trimethoxyphenyl)-,
phenylmethyl ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 125456-08-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 125456-08-8 CAPLUS
CN 2,3(1H)-Isoquinolinedicarboxylic acid,
3,4-dihydro-6,7-dimethoxy-1-(3,4,5-trimethoxyphenyl)-, 2-(phenylmethyl)
ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L5 ANSWER 35 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1989:497608 CAPLUS Full-text
DN 111:97608
OREF 111:16437a,16440a
TI Carbon-transfer reactions with heterocycles. Part 3. Synthetic
equivalence of oxazolidines with carbonyl compounds
AU Singh, Harjit; Sarin, Rakesh
CS Dep. Chem., Guru Nanak Dev Univ., Amritsar, 143005, India
SO Journal of Chemical Research, Synopses (1988), (10), 322-3
CODEN: JRPSDC; ISSN: 0308-2342
DT Journal
LA English
OS CASREACT 111:97608
GI



Page 162 of 219

AB Oxazolidines transfer C-2 carbon units to binucleophiles to furnish heterocycles including β-carboline and isoquinoline alkaloids. Thus, the oxazolidine I was treated with tryptamine in MeCN containing acid to give its carboline II.

IT 33033-84-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 33033-84-0 CAPLUS

CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-1-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L5 ANSWER 36 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1989:154166 CAPLUS Full-text
DN 110:154166
OREF 110:25491a,25494a
TI Preparation of di- and tetrahydroisoquinoline derivatives as cytostatics
PA Duphar International Research B. V., Neth.
SO Jpn. Kokai Tokkyo Koho, 13 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	JP 62283960	A	19871209	JP 1987-119169	19870518	<--
	CA 1330560	C	19940705	CA 1987-537195	19870515	<--
	DK 8702503	A	19871122	DK 1987-2503	19870518	<--
	AU 8773149	A	19871126	AU 1987-73149	19870518	<--
	ZA 8703561	A	19871230	ZA 1987-3561	19870518	<--
	IL 82555	A	19910512	IL 1987-82555	19870518	<--
	EP 251361	A1	19880107	EP 1987-200926	19870519	<--
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE					
	US 5162335	A	19921110	US 1989-480755	19891127	<--
PRAI	NL 1986-1279	A	19860521			
	US 1987-50425	B2	19870518			
	US 1987-123326	B1	19871120			

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
GI



I



II

AB Title compds. I [R, R1, R2 = H, halo, CF3, C1-4 alkyl, C1-4 alkoxy; RR1, R1R2, R2R13 = hydrocarbenyl (may be interrupted with 1-3 N, O, or S) to form 5-7 membered cycle which may be substituted with C1-4 alkyl, halo, oxo, or thioxo; R3 = H, OH, C1-4 alkoxy, alkanoyloxy; R4 = H, CO2R11, CON(R12)2, CH2OR15 (R11, R12 = C1-4 alkyl; R15 = H, C1-4 alkyl, tetrahydropyranyl, C1-4 alkanoyl, mono- or di-C1-4 alkyl substituted carbamoyl); R5 = H, C1-4 alkanoyl, alkyl; R4R5 = CH2XZ (X = O, NH, alkyl-substituted N; Z = CO, CS, SO, CH2); R6 = H; R5R6 = bond; R7, R9 = H, C1-4 alkoxy; R8 = H, C1-4 alkoxy, alkanoyloxy, OH, halo; R7R8, R8R9 = OCH2O, O(CH2)2O; R10 = H, C1-4 alkyl, alkoxy; R14 = H, Me] are prepared from N-phenethylbenzamides II. A solution of II (R = R3 = R10 = R13 = R14 = H; R1R2 = OCH2O; R7 = R8 = R9 = MeO) was successively treated with PCl5 and AlCl3 to give 92% I (R = R3 = R10 = R13 = R14 = H; R1R2 = OCH2O; R4 = AcOCH2; R5R6 = bond; R7 = R8 = R9 = MeO), which was hydrolyzed with K2CO3 in MeOH to afford 83% I (R4 = CH2OH). The latter product in THF was treated with AlH3 (generated from AlCl3 and LiAlH4 in situ) for 1.5 h to give 97% I (R5 = R6 = H), which in CH2Cl2 was treated with C12CO in the presence of NEt3 to afford 89% I [R = R3 = R6 = R10 = R13 = R14 = H; R1R2 = OCH2O; R4R5 = CH2OC(O); R7 = R8 = R9 = MeO; cis-form at 1,3-position] (III). III at 15 μg/mL showed .apprx.50-100% control of human cell lines.

IT 118068-19-2P 118068-20-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of isoquinoline cytostatics)

RN 118068-19-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2,3,4-tetrahydro-6,7-dihydroxy-1-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 118068-20-5 CAPLUS

CN 2,3(1H)-Isoquinolinedicarboxylic acid, 3,4-dihydro-6,7-dihydroxy-1-(3,4,5-trimethoxyphenyl)-, 3-methyl

2-(phenylmethyl) ester (CA INDEX NAME)



OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

L5 ANSWER 37 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1984:610940 CAPLUS Full-text
DN 101:210940
OREF 101:31959a
TI Synthesis and radioprotectant properties of some derivatives of 6-hydroxy-1,2,3,4-tetrahydroisoquinoline
AU Alpatova, T. V.; Klimova, A. D.; Kulinskii, V. I.; Mirzoyan, V. S.; Mirzoyan, A. T.; Yashunskii, V. G.
CS Inst. Biofiz., Moscow, USSR
SO Khimiko-Farmatsevticheskii Zhurnal (1984), 18(4), 444-9
CODEN: KHFZAN; ISSN: 0023-1134
DT Journal
LA Russian
OS CASREACT 101:210940
GI



AB Cyclocondensation of 3-HOC6H4CH(OH)CH2NHCH2Ph with R2CHO (R2 = Me, 2-, 4-HOC6H4, 4-pyridyl) gave 36.5-88% isoquinolinols I (R = PhCH2, R1 = H, R2 as above) which were debenzylated by Pd-C to give 47-76% I (R = R1 = H, R2 = Me, 2-, 4-HOC6H4). Cyclocondensation of 3-HOC6H4CH(OH)CH2NHMe with R2CHO gave 30-50% I (R = Me, R1 = H, R2 = H, 2-HOC6H4, 4-MeOC6H4). Addnl. obtained were 3-HOC6H4CH(OH)CH2NRCHR1R2 (R = R1 = H, R2 = Me, 4-MeOC6H4; R = Me, R1 = R2 = H; R = H, R1 = R2 = Me). Mice treated with I (R = PhCH2, R1 = H, R2 = Me) (LD50 3521 ± 56 μmol/kg) increased their survival time to 13 ± 6% at 50 μmol/kg dosage compared to 5.6 ± 1.3 for a control.
IT 93202-94-9 93202-96-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(radioprotectant properties of)
RN 93202-94-9 CAPLUS
CN 4,6-Isoquinolinediol, 1,2,3,4-tetrahydro-1-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 93202-96-1 CAPLUS
CN 4,6-Isoquinolinediol, 1,2,3,4-tetrahydro-2-(phenylmethyl)-1-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L5 ANSWER 38 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1984:530578 CAPLUS Full-text
DN 101:130578
OREF 101:19861a,19864a
TI Synthesis of benzazepinespirocycloalkanes. IV. 1,2-Substituted-1,2,3,4-tetrahydrospiro-5-cyclopentane-(5H)-2-benzazepines
AU Solomina, L. P.; Pirdzhanov, L. Sh.; Markaryan, E. A.
CS Inst. Tonkoi Org. Khim. im. Mndzhoyana, Yerevan, USSR
SO Armyanskii Khimicheskii Zhurnal (1984), 37(4), 253-7
CODEN: AYKZAN; ISSN: 0515-9628
DT Journal
LA Russian
OS CASREACT 101:130578
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Condensation of cyclopentaneethanamine I and spiro[benzazepine-cyclopentane] II with 3,4,5-(MeO)2RC6H2(CH2)nCOCl (R = MeO, n = 0; R = H, n = 1) yields amides III and IV. Cyclodehydration and reduction of III with POCl3 and NaBH4 gives V [R1 = 3,4-(MeO)2C6H3CH2, 3,4,5-(MeO)3C6H2, R2 = H] which were N-methylated by CH2O-HCO2H to give V (R2 = Me). Reduction of IV by LiAlH4 gave 50.0 and 42.3% V [R1 = Me, R2 = 3,4-(MeO)2C6H3CH2CH2, 3,4,5-(MeO)3C6H2CH2].
IT 91935-74-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and N-methylation of)
RN 91935-74-9 CAPLUS
CN Spiro[5H-2-benzazepine-5,1'-cyclopentane],
1,2,3,4-tetrahydro-7,8-dimethoxy-1-(3,4,5-trimethoxyphenyl)-,
hydrochloride (1:1) (CA INDEX NAME)



IT 91935-76-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 91935-76-1 CAPLUS
CN Spiro[5H-2-benzazepine-5,1'-cyclopentane],
1,2,3,4-tetrahydro-7,8-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-,
hydrochloride (1:1) (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L5 ANSWER 39 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1982:509845 CAPLUS Full-text
DN 97:109845
OREF 97:18269a,18272a
TI A new variant of the internal α-amidoalkylation reaction: synthesis
of 1-aryl-3-oxo-2,3-dihydroisoquinolines and cryptostyline III
AU Venkov, A.; Lukanov, L.; Mollov, N.
CS Dep. Chem., Univ. Plovdiv, Plovdiv, 4000, Bulg.
SO Synthesis (1982), (6), 486-7
CODEN: SYNTBF; ISSN: 0039-7881

DT Journal
LA English
GI



I

AB Isoquinolinones I [R = H, OMe; R1 = Me, Ph, 4-MeOC6H4; R2 = H, 4-O2N, 4-Cl, 4-F, 3,4,5-(MeO)3] were obtained at 32-67% yield by treating 3,4,5-R(MeO)2C6H2CH2CO2H with R2C6H4CONHR1 in the presence of POCl3. Cryptostyline III was prepared by 2-stage reduction of I [R = H, R1 = Me, R2 = 3,4,5-(MeO)3].

IT 82801-28-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)

RN 82801-28-3 CAPLUS
CN 3(2H)-Isoquinolinone, 1,4-dihydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



IT 22324-83-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 22324-83-0 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L5 ANSWER 40 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1981:603702 CAPLUS Full-text
DN 95:203702
OREF 95:34033a
TI Use of a benzyl protective group in the synthesis of tetrahydroisoquinoline derivatives
AU Alpatova, T. V.; Yashunskii, V. G.
CS Inst. Biofiz., Moscow, 123182, USSR
SO Khimiya Geterotsiklicheskikh Soedinenii (1981), (8), 1084-7
CODEN: KGSSAQ; ISSN: 0453-8234
DT Journal
LA Russian
OS CASREACT 95:203702
GI



II



III



IV

AB Cyclocondensation of 3-HOC6H4CH(OH)CH2NHCH2Ph (I) with 3,4,5-RR1R2C6H2CHO (R,R1,R2 = MeO,HO,H; MeO,MeO,MeO; H,Me2N,H) gave benzylisoquinolines II (R3 = benzyl), which were debenzylated by hydrogenolysis over Pd black to give II (R3 = H). I and CH2O gave a mixture of 2-benzyl-1,2,3,4-tetrahydroisoquinoline-4,6-diol and 2-benzyl-1,2,3,4-tetrahydroisoquinoline-4,8-diol; these compds. were also debenzylated. Debenzylation-cyclocondensation of III gave lactam IV.

IT 79677-06-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and debenzylation of)

RN 79677-06-8 CAPLUS

CN 4,6-Isoquinolinediol, 1,2,3,4-tetrahydro-2-(phenylmethyl)-1-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)



IT 72512-61-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 72512-01-7 CAPLUS
CN 4,6-Isoquinolinediol, 1,2,3,4-tetrahydro-1-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L5 ANSWER 41 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1981:198 CAPLUS Full-text
DN 94:198
OREF 94:39a,42a
TI Pharmacological studies on some derivatives of the isoquinoline series
AU Nikolova, M.; Ivanova, N.
CS Bulg.
SO Trudove na Nauchnoizsledovatelskiya Khimikofarmatsevtichen Institut (1978), 10, 211-19
CODEN: TKZGAG; ISSN: 0371-8972
DT Journal
LA Bulgarian
GI



I



II



III

AB Among 12 title compds. I (R1 and R2 and R3 = H, Cl, or MeO; R4 = NO2, NH2, or NHCOCBr(Me)2) II (R1 and R2 and R3 = MeO; R4 = NO2; R5 = CH2CO2Et), and III (R1 and R2 and R3 = H, Cl; R4 = H, Et, CHMe2; R5 = H, NH2, NO2), evaluated pharmacol. in vivo, III showed weak central depressive activity and lower toxicity than I. All compds. had low hypotensive activity and little effect on the smooth muscle of gastrointestinal tract and bronchi.

IT 75230-95-4

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. of)

RN 75230-95-4 CAPLUS

CN 2(1H)-Isoquinolineacetic acid, 3,4-dihydro-6,7-dimethoxy-1-(3,4,5-trimethoxy-2-nitrophenyl)-, ethyl ester (CA INDEX NAME)



L5 ANSWER 42 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1980:531967 CAPLUS Full-text

DN 93:131967

OREF 93:21029a,21032a

TI Carbon-13 NMR spectra of 4-hydroxytetrahydroisoquinolinium chlorides

AU Baddeley, G. Vernon; Quessy, Stephen N.; Williams, Lyall R.

CS Sch. Chem., Univ. New South Wales, Kensington, 2033, Australia

SO Australian Journal of Chemistry (1980), 33(2), 447-50
CODEN: AJCHAS; ISSN: 0004-9425

DT Journal

LA English

AB The natural abundance 13C NMR spectra of tetrahydroisoquinolinium salts are reported and discussed in terms of the substitution profile and stereochem. of the salts.

IT 72511-98-9 72512-01-7
RL: PRP (Properties)
(carbon-13 NMR of)

RN 72511-98-9 CAPLUS

CN 4,6,8-Isoquinolinetriol, 1,2,3,4-tetrahydro-1-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 72512-01-7 CAPLUS

CN 4,6-Isoquinolinediol, 1,2,3,4-tetrahydro-1-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L5 ANSWER 43 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1980:58575 CAPLUS Full-text

DN 92:58575

OREF 92:9699a,9702a

TI Synthesis and biological evaluation of tetrahydroisoquinolin-4-ol derivatives

AU Quessy, Stephen N.; Williams, Lyall R.

CS Sch. Chem., Macquarie Univ., North Ryde, 2113, Australia

SO Australian Journal of Chemistry (1979), 32(6), 1317-27
CODEN: AJCHAS; ISSN: 0004-9425

DT Journal

LA English

OS CASREACT 92:58575

GI



AB Hydroxytetrahydroisoquinolines I (R = R1 = H, Me), II, III (R2, R3 = H, MeO), and IV, cyclic analogs of phenylethanolamines, were prepared I-IV had no β-adrenocepter stimulating activity.

IT 72511-98-9P 72512-01-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 72511-98-9 CAPLUS

CN 4,6,8-Isoquinolinetriol, 1,2,3,4-tetrahydro-1-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)



RN 72512-01-7 CAPLUS

CN 4,6-Isoquinolinediol, 1,2,3,4-tetrahydro-1-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)



L5 ANSWER 44 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1978:121486 CAPLUS Full-text
DN 88:121486
OREF 88:19081a,19084a
TI Polymethoxylated isoquinolines as potential antimitotic agents
AU Iorio, Maria; Brossi, Arnold; Chignell, Colin F.
CS Lab. Chem., Natl. Inst. Arthritis, Metab. Dig. Dis., Bethesda, MD, USA
SO Heterocycles (1978), 9(1), 1-6
CODEN: HTCYAM; ISSN: 0385-5414
DT Journal
LA English
GI



I



II



III

AB The sendaverine derivs. I (R = MeO, R1 = H; R = H, R1 = MeO) were prepared by condensation of mescaline with 2,4,5-(MeO)3C6H2CHO and 3,4,5-(MeO)3C6H2CHO and reduction of the Schiff bases to give II, which were cyclized. The cryptostyline derivative III was prepared by cyclization of 3,4,5-(MeO)3C6H2CONHCH2CH2C6H2(OMe)3-3,4,5 followed by reduction and dehydrogenation. Using colchicine as a standard none of the compds. showed any binding affinity to the rat brain microtubule protein.

IT 65967-39-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and dehydration of)
RN 65967-39-7 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7,8-trimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, ethanedioate (1:?) (CA INDEX NAME)

CM 1

CRN 65967-38-6
CMF C22 H29 N O6



CM 2

CRN 144-62-7
CMF C2 H2 O4

IT 65967-37-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and methylation of)
RN 65967-37-5 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7,8-trimethoxy-1-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



L5 ANSWER 45 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1977:121306 CAPLUS Full-text
DN 86:121306
OREF 86:19159a,19162a
TI 1,4-Benzodiazepines. IV. 6-Phenyl- and 6-thienyltetrahydroisoquinolino[2,1-d]-7H-[1,4]-benzodiazepines

AU Ivanov, Ch.; Shvedov, V. I.
CS Sci.-Res. Chem.-Pharm. Inst., Sofia, Bulg.
SO Khimiko-Farmatsevticheskii Zhurnal (1976), 10(7), 44-51
CODEN: KHFZAN; ISSN: 0023-1134
DT Journal
LA Russian
GI



I



II

AB Isoquinolinobenzodiazepines I (R1 = Cl, H, MeO, R2 = H, Cl, MeO, R3 = H, MeO, R4 = Ph, 4-biphenylyl, 4-BrC6H4, 4-MeOC6H4, 4-O2NC6H4, 2-thienyl) were obtained in 15-33% yields by reduction of II with NaBH4 followed by cyclization with R4COCH2Br. Addnl. I (R1 = Cl, R2 = R3 = H, R4 = Ph, 4-biphenylyl, 4-BrC6H4, 4-MeOC6H4, 4-O2NC6H4) were obtained from II by cyclization with R4COCH2Br followed by reduction with NaBH4.
IT 62206-18-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclization by phenacyl bromides)
RN 62206-18-2 CAPLUS
CN Benzenamine, 2,3,4-trimethoxy-6-(1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl)- (CA INDEX NAME)



L5 ANSWER 46 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1976:164575 CAPLUS Full-text
DN 84:164575
OREF 84:26711a,26714a
TI Isoquinoline derivatives. XI. Synthesis and pharmacological activity of 1-arylalkyl-4-spirocyclohexane-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolines and some of their derivatives
AU Markaryan, E. A.; Arustamyan, Zh. S.; Vasilyan, S. S.; Markaryan, K. Zh.
CS Inst. Tonkoi Org. Khim. im. Mndzhoyana, Yerevan, USSR
SO Armyanskii Khimicheskii Zhurnal (1975), 28(10), 829-35
CODEN: AYKZAN; ISSN: 0515-9628

DT Journal
LA Russian
OS CASREACT 84:164575
GI





AB Spiro[cyclohexaneisoquinoline] derivs. I [R = Ph, 3,4-(MeO)2C6H3, 3,4,5-(MeO)3C6H2, Ph2CH, n = 0,1] were obtained in 45.3-69.4% yields by cyclization of amides II with POCl3. Reduction of I by NaBH4 gave 67.3-81.2% 1,2-dihydro derivs. Cyclocondensation of the appropriate 1,2-dihydro derivative with HCHO gave 55.1 and 56% berbines III (n = 1,2). I were useful in treatment of hypertension, as muscle relaxants, and as antiarrhythmics.

IT 59021-77-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 59021-77-1 CAPLUS

CN Spiro[cyclohexane-1,4'(1'H)-isoquinoline], 2',3'-dihydro-6',7'-dimethoxy-1'-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L5 ANSWER 47 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1976:4818 CAPLUS Full-text
DN 84:4818
OREF 84:813a,816a
TI 6,7-Dihydroxy-1-(3,4,5-trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinoline
IN Vasvari, Mrs. Arpad; Meszaros, Zoltan; Nagy, Gabor; Hermecz, Istvan; Horvath, Agnes; David, Agoston; Mandi, Attila; Pajor, Aniko
PA Chinoin Gyogyszer es Vegyeszeti Termekek Gyara Rt., Hung.
SO Hung. Teljes, 13 pp.
CODEN: HUXXBU
DT Patent
LA Hungarian
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI HU 9519		19750328	HU 1973-CI1389	19730628 <--

AB 3,4-(HO)2C6H3CH2CH2NH2.HBr added to excess Na 3,4,5-trimethoxyphenylglycidate in aqueous HCl-AcOH, the mixture stirred 2 hr at 20° and 5 hr at 70-80° and pH 1 gave 54% title product HCl salt, m. 225-6° (MeOH).
IT 57529-51-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 57529-51-8 CAPLUS
CN 6,7-Isoquinolinediol, 1,2,3,4-tetrahydro-1-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L5 ANSWER 48 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1975:593279 CAPLUS Full-text
DN 83:193279
OREF 83:30405a,30408a
TI Heterocyclic compounds
IN Ott, Hans; Suess, Rudolf
PA Sandoz-Patent-G.m.b.H., Fed. Rep. Ger.
SO Ger. Offen., 29 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 2503156	A1	19750807	DE 1975-2503156	19750127 <--
FI 7500205	A	19750806	FI 1975-205	19750127 <--
SE 7500859	A	19750806	SE 1975-859	19750127 <--
DK 7500242	A	19750929	DK 1975-242	19750127 <--
DK 136189	B	19770829		

	DK 136189	C	19780130			
	NO 7500263	A	19750806	NO 1975-263	19750129	<--
	NL 7501159	A	19750807	NL 1975-1159	19750131	<--
	BE 825124	A1	19750804	BE 1975-153007	19750203	<--
	DD 117216	A5	19760105	DD 1975-183969	19750203	<--
	AU 7577843	A	19760805	AU 1975-77843	19750203	<--
	HU 169923	B	19770228	HU 1975-SA2741	19750203	<--
	GB 1497722	A	19780112	GB 1975-4516	19750203	<--
	GB 1497723	A	19780112	GB 1977-30857	19750203	<--
	JP 50108297	A	19750826	JP 1975-14021	19750204	<--
	AT 7500799	A	19790115	AT 1975-799	19750204	<--
	AT 351536	B	19790725			
	CA 1055944	A1	19790605	CA 1975-219303	19750204	<--
	FR 2259611	A1	19750829	FR 1975-3547	19750205	<--
	FR 2259611	B1	19800111			
	ZA 7500743	A	19760929	ZA 1975-743	19750205	<--
	US 4087530	A	19780502	US 1976-670111	19760325	<--
PRAI	CH 1974-1550	A	19740205			
	US 1975-545540	A2	19750130			
	GB 1975-4516	A	19750203			
	GB 1975-18178	A	19750917			
	GB 1975-38177	A	19750917			

OS MARPAT 83:193279

GI For diagram(s), see printed CA Issue.

AB Broncholytic (no data) cis-octahydrobenzonaphthyridines I (R = H, 8-OH, 8-OMe, 9-OMe, 9-OH; R1 = H, 3-OMe, 3-Cl, 3-OH, 2-OH; R2 = H, NH2, NHAc, F, Me, Cl, OMe, OH, NO2, NMe2; R2 = H, OMe, OH) (39 compds.) were prepared by reducing the 1,2,3,4,4a,10b-hexahydro analogs with PtO, or NaBH4.

IT 57251-31-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 57251-31-7 CAPLUS

CN Benzo[c][1,6]naphthyridine, 1,2,3,4,4a,5,6,10b-octahydro-9-methoxy-2-methyl-6-(3,4,5-trimethoxyphenyl)-, dihydrochloride, (4aα,6β,10bα)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L5 ANSWER 49 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1975:80346 CAPLUS Full-text

DN 82:80346

OREF 82:12793a,12796a
TI Experimental studies on the antitumor effect of ethidium bromide and related substances
AU Nishiwaki, Hiroshi; Miura, Moriji; Imai, Kuniyuki; Ohno, Ryuzo; Kawashima, Kohei; Ezaki, Koji; Ueda, Ryuzo; Yoshikawa, Haruya; Nagata, Kouichiro; et al.
CS Sch. Med., Nagoya Univ., Nagoya, Japan
SO Cancer Research (1974), 34(10), 2699-703
CODEN: CNREA8; ISSN: 0008-5472
DT Journal
LA English
GI For diagram(s), see printed CA Issue.
AB Ethidium bromide [1239-45-8] increased by ≤200% the life span of mice with tumor 6C3HED-OG, and by ≤83% the life span of mice with L5178Y. No such effect was noted in mice with tumors L1210, EL4, 6C3HED-RG, RADA1, or Walker carcinosarcoma 256. Of the 14 related compds. tested, PD-MY-001 (I) [53409-06-6] and PD-MY-003 (II) [38483-26-0] also increased the survival time of mice with 6C3HED-OG by ≤200%. Ethidium bromide and these 2 newly synthesized compds. are apparently antitumor agents with a unique mechanism of action.
IT 53954-69-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neoplasm inhibition by)
RN 53954-69-1 CAPLUS
CN Isoquinoline, 1-(2-chloro-3,4,5-trimethoxyphenyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, hydrochloride (1:1) (CA INDEX NAME)



OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

L5 ANSWER 50 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1974:435571 CAPLUS Full-text
DN 81:35571
OREF 81:5709a,5712a
TI Orchidaceae alkaloids. XXXIX. Isolation of (-)-cryptostyline I, II, III and two quaternary salts from Cryptostylis erythroglossa. Biosynthetic studies of (-)-cryptostyline I
AU Agurell, Stig; Granelli, Ingrid; Leander, Kurt; Luning, Bjorn; Rosenblom, Jan
CS Fac. Pharm., Stockholm, Swed.
SO Acta Chemica Scandinavica, Series B: Organic Chemistry and Biochemistry (1974), 28(2), 239-43
CODEN: ACBOCV; ISSN: 0302-4369
DT Journal
LA English

AB (-)-Cryptostyline I, II, and III, together with 1-(3,4-methylenedioxyphenyl)-6,7-dimethoxy-2-methyl-3,4- dihydroisoquinolinium iodide and 1-(3,4-methylenedioxyphenyl)-6,7- dimethoxy-2-methylisoquinolinium chloride have been isolated from Cryptostylis erythroglossa. The biosynthesis of (-)-cryptostyline I has been studied using radioactive precursors and the position of the radio-label determined by degradation The biosynthetic results show that tyrosine and 3,4-dihydroxyphenylalanine as well as tyramine and dopamine are specifically incorporated. The finding that 3-hydroxy-4-methoxyphenethylamine is better incorporated than the isomeric 4-hydroxy-3-methoxy-phenethylamine suggests that the ring closure to the tetrahydroisoquinoline skeleton is facilitated by a para-hydroxy group.

IT 33033-86-2
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(of Cryptostylis erythroglossa)

RN 33033-86-2 CAPLUS

CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L5 ANSWER 51 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1973:525682 CAPLUS Full-text

DN 79:125682

OREF 79:20407a,20410a

TI Syntheses of heterocyclic compounds. DXXVII. Absolute configuration of 1,2,3-4-tetrahydro-1-phenylisoquinolines

AU Kametani, Tetsuji; Shibuya, Shiroshi; Sugi, Hideo; Fukumoto, Keiichiro

CS Pharm. Inst., Tohoku Univ., Sendai, Japan

SO Journal of Heterocyclic Chemistry (1973), 10(4), 451-3
CODEN: JHTCAD; ISSN: 0022-152X

DT Journal

LA English

AB The absolute configuration at the C-1 position of 1,2,3,4-tetrahydro-1-phenylisoquinolines can be deduced from the CD curves of either the free base or its methiodide. The absolute configuration of (+)-2-amino-1-(3-hydroxyphenyl)ethanol was revised and found to have R-configuration.

IT 43090-63-8P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and circular dichroism of)

RN 43090-64-8 CAPLUS

CN Isoquinolinium, 1,2,3,4-tetrahydro-6,7-dimethoxy-2,2-dimethyl-1-(3,4,5-trimethoxyphenyl)-, iodide, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 43090-65-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 43090-65-9 CAPLUS
CN Isoquinolinium, 1,2,3,4-tetrahydro-6,7-dimethoxy-2,2-dimethyl-1-(3,4,5-trimethoxyphenyl)-, iodide, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 22325-16-2 33033-86-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(quaternization of)
RN 22325-16-2 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 33033-86-2 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 52 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1973:159937 CAPLUS Full-text
DN 78:159937
OREF 78:25687a,25690a
TI Orchidaceae alkaloids. XXXIV. Absolute configuration of cryptostyline I, II, and III. Three 1-phenyl-1,2,3,4-tetrahydroisoquinolines from Cryptostylis fulva
AU Leander, Kurt; Luning, Bjorn; Westin, Leif
CS Dep. Org. Chem., Univ. Stockholm, Stockholm, Swed.
SO Acta Chemica Scandinavica (1947-1973) (1973), 27(2), 710
CODEN: ACSAA4; ISSN: 0001-5393
DT Journal
LA English
GI For diagram(s), see printed CA Issue.
AB Cryptostyline I, II and III isolated from Cryptostylis fulva had structures I, II, and III, resp., based on CD and x-ray crystallog.
IT 22325-16-2
RL: PRP (Properties)
(structure and configuration of)
RN 22325-16-2 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L5 ANSWER 53 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1973:111557 CAPLUS Full-text
DN 78:111557
OREF 78:17915a,17918a
TI Absolute configuration of cryptostylines I, II, and III by x-ray analysis and aromatic chirality method
AU Blount, J. F.; Toome, V.; Teitel, S.; Brossi, A.
CS Chem. Res. Dep., Hoffman-LaRoche Inc., Nutley, NJ, USA
SO Tetrahedron (1973), 29(1), 31-9
CODEN: TETRAB; ISSN: 0040-4020
DT Journal
LA English
OS CASREACT 78:111557
GI For diagram(s), see printed CA Issue.
AB Single crystal x-ray anal. of unnatural cryptostyline II (I, R = Me) hydrobromide established its absolute configuration as R. Thus, the natural isomer (II, R = H, R1 = R2 = OMe) and the related alkaloids cryptostyline I (II, R = H, R1R2 = OCH2O) and cryptostyline III (II, R = R1 = R2 = OMe) have S configurations. The orthorhombic crystals of I.HBr (R = Me), space group P212121, had a 10.162, b 12.352, c 16.456 Å, d.(observed) 1.37, and d.(calculated) 1.364, for Z = 4. The structure was solved by the heavy atom method and refined by least squares to R 0.031 for 1882 observed reflections. The configuration was confirmed by the aromatic chirality method and by the CD spectrum of the monophenol (I, R = H).
IT 22325-16-2
RL: PRP (Properties)
(absolute configuration of)
RN 22325-16-2 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L5 ANSWER 54 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1973:4145 CAPLUS Full-text
DN 78:4145
OREF 78:691a,694a
TI Optically active 1-phenylisoquinolines
IN Kametani, Tetsuji
PA Grelan Pharmaceutical Co., Ltd.
SO Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 47025183	B4	19721019	JP 1971-13124	19710312 <--

AB Optically inactive 1-phenylisoquinolines were treated with optically active salt forming agent so that one of the optically active salts could be selectively crystallized E.g., 1.2,3.4-tetrahydro-o,p-dimethoxy-1-(3,4,5-trimethoxyphenyl)isoquinoline, prepared by reduction of the corresponding 3,4-dihydro compound, was treated with di-p-toluoyl-(+)-tartaric acid in Me2CO and the separated crystals decomposed with Na2CO3 solution to give (-)-compound

IT 32886-69-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 32886-69-4 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-1-(3,4,5-trimethoxyphenyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 33033-84-0
RL: PROC (Process)
(resolution of)
RN 33033-84-0 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-1-(3,4,5-trimethoxyphenyl)-
(CA INDEX NAME)



L5 ANSWER 55 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1972:72372 CAPLUS Full-text
DN 76:72372
OREF 76:11649a,11652a
TI Isoquinoline derivatives. V. Synthesis of some 1-substituted 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-4-spirocyclopentanes and their analogs
AU Mndzhoyan, A. L.; Markaryan, E. A.; Arustamyan, Zh. S.; Marashyan, E. S.
CS Inst. Tonkoi Org. Khim., Erevan, USSR
SO Khimiya Geterotsiklicheskikh Soedinenii (1971), 7(5), 637-40
CODEN: KGSSAQ; ISSN: 0132-6244
DT Journal
LA Russian
GI For diagram(s), see printed CA Issue.
AB A series of the title compds. (I, R = H, MeO; R1 = H, MeO; R2 = MeO, H; n = 0, 1) [prepared by Bischler-Napieralski reaction of the 1-amidomethyl-1-(3,4-dimethoxyphenyl)cyclopentane (II, n = 0, 1) in boiling PhMe with POCl3 and subsequent reduction with LiAlH4 of the 1,2-double bond in the 6,7-dimethoxy-3,4-dihydroisoquinoline-4-spirocyclopentane (III, n = 0, 1)], and the 1-aminomethyl-1-(3,4- dimethoxyphenyl)cyclopentanes (IV, n = 0, 1)(prepared from II by reduction with LiAlH4) in the form of their hydrochlorides produced a decrease in blood pressure of about 30 mm of Hg when given intravenously in a dose 1-3 mg/kg. II were prepared from the corresponding amines (V) (obtained from 3,4-(MeO)2C6H4-CH2CN via alkylation with Br(CH2)4Br in the presence of NaNH2 followed by reduction with LiAlH4) and acid chlorides in C6H6 in the presence of stoichiometric amts. of pyridine.
IT 34976-64-2
RL: PROC (Process)
(preparation of)
RN 34976-64-2 CAPLUS
CN Spiro[cyclopentane-1,4'(1'H)-isoquinoline], 2',3'-dihydro-6',7'-dimethoxy-1'-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L5 ANSWER 56 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1971:529977 CAPLUS Full-text
DN 75:129977
OREF 75:20531a,20534a
TI Synthesis and absolute configuration of cryptostylines I, II, and III
AU Brossi, A.; Teitel, S.
CS Chem. Res. Dep., Hoffmann-La Roche Inc., Nutley, NJ, USA
SO Helvetica Chimica Acta (1971), 54(6), 1564-71
CODEN: HCACAV; ISSN: 0018-019X
DT Journal
LA English
GI For diagram(s), see printed CA Issue.
AB The title compds. [I (RR1 = OCH2O, R2 = H; R = R1 = OMe, R2 = H; R = R1 = R2 = OMe)] were prepared by the reductive N-methylation of secondary norcryptostylines. The natural I possessed the (S) configuration. The reported easy racemization ability of the natural I was traced to optical impurities in the original preparation
IT 32886-69-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and O.R.D. of)
RN 32886-69-4 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-1-(3,4,5-trimethoxyphenyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 33033-86-2P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and absolute configuration of)
RN 33033-86-2 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-

trimethoxyphenyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 22325-16-2P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and absolute configuration of, O.R.D. and)
RN 22325-16-2 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 33033-84-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and resolution of)
RN 33033-84-0 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-1-(3,4,5-trimethoxyphenyl)-
(CA INDEX NAME)



IT 32886-78-4P 33755-95-2P 33770-51-3P

33839-85-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 32886-70-7 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-1-(3,4,5-trimethoxyphenyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 33755-95-2 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, hydrobromide, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 33770-51-3 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, hydrobromide (1:1), (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 33838-85-6 CAPLUS

CN L-xylo-Hexulofuranosonic acid, 2,3:4,6-di-O-isopropylidene-, α-, compd. with (S)-(-)-1,2,3,4-tetrahydro-6,7-dimethoxy-1-(3,4,5-trimethoxyphenyl)isoquinoline (1:1) (8CI) (CA INDEX NAME)

CM 1

CRN 32886-69-4
CMF C20 H25 N O5

Absolute stereochemistry.



CM 2

CRN 18467-77-1
CMF C12 H18 O7

Absolute stereochemistry. Rotation (-).



OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

L5 ANSWER 57 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1971:464052 CAPLUS Full-text
DN 75:64052
OREF 75:10159a,10162a
TI Synthesis of heterocyclic compounds. CCCXCVII. Absolute configuration of cryptostyline. III
AU Kametani, T.; Sugi, H.; Shibuya, S.
CS Pharm. Inst., Tohoku Univ., Sendai, Japan
SO Tetrahedron (1971), 27(12), 2409-14
CODEN: TETRAB; ISSN: 0040-4020
DT Journal
LA English
GI For diagram(s), see printed CA Issue.
AB Optical resolution of (±)-1,2,3,4-tetrahydro-6,7-dimethoxy-1-(3,4,5-trimethoxyphenyl)isoquinoline [(±)-I] with di-p-toluoyl-(+)-tartaric acid gave (-)-(I) and (+)-1,2,3,4-tetrahydro-6,7-dimethoxy-1-(3,4,5-trimethoxyphenyl)isoquinoline. I was transformed to (+)-cryptostyline III (II). A method for the stereochem. study of cryptostyline III by correlation of ORD and CD spectra with those of (+) (R)-1,2,3,4-tetrahydro-6-methoxy-2-methyl-1-phenylisoquinoline.
IT 22325-16-2
RL: PRP (Properties)
(configuration of, absolute)
RN 22325-16-2 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 32886-68-3P 32886-69-4P 32886-70-7P
33033-85-1P 33033-86-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 32886-68-3 CAPLUS
CN Butanedioic acid, 2,3-bis[(4-methylbenzoyl)oxy]-, [S-(R*,R*)]-, compd. with (S)-1,2,3,4-tetrahydro-6,7-dimethoxy-1-(3,4,5-trimethoxyphenyl)isoquinoline (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 32886-69-4
CMF C20 H25 N O5

Absolute stereochemistry.



CM 2

CRN 32634-68-7
CMF C20 H18 O8

Absolute stereochemistry. Rotation (+).



RN 32886-69-4 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-1-(3,4,5-trimethoxyphenyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 32886-70-7 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-1-(3,4,5-trimethoxyphenyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 33033-85-1 CAPLUS
CN Butanedioic acid, 2,3-bis[(4-methylbenzoyl)oxy]-, [R-(R*,R*)]-, compd. with (R)-1,2,3,4-tetrahydro-6,7-dimethoxy-1-(3,4,5-trimethoxyphenyl)isoquinoline (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 32886-70-7
CMF C20 H25 N O5

Absolute stereochemistry.



CM 2

CRN 32634-66-5
CMF C20 H18 O8

Absolute stereochemistry. Rotation (-).



RN 33033-86-2 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 33033-84-0
RL: PROC (Process)
(resolution of)
RN 33033-84-0 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-1-(3,4,5-trimethoxyphenyl)-
(CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L5 ANSWER 58 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1969:106718 CAPLUS Full-text
DN 70:106718
OREF 70:19943a,19946a
TI Orchidaceae alkaloids. XI. Three
1-phenyl-1,2,3,4-tetrahydroisoquinolines from Cryptostylis fulva
AU Leander, Kurt; Luning, Bjorn; Ruusa, Ene
CS Univ. Stockholm, Stockholm, Swed.
SO Acta Chemica Scandinavica (1947-1973) (1969), 23(1), 244-8
CODEN: ACSAA4; ISSN: 0001-5393
DT Journal
LA English
AB Three 1-phenyl-2-methyl-6,7-dimethoxy-1,2,3,4-tetrahydroiso-quinolines were isolated from C. fulva. The 3 alkaloids differ in the substitution pattern of the 1-phenyl group, being 3,4-methylenedioxy, 3,4-dimethoxy, and 3,4,5-trimethoxy, resp. Their structures were assigned by spectral methods and by synthesis.
IT 22325-16-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(new alkaloid from Cryptostylis fulva, structure of)
RN 22325-16-2 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 22324-83-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 22324-83-0 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

L5 ANSWER 59 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1965:93561 CAPLUS Full-text
DN 62:93561
OREF 62:16783g-h
TI Pharmacological activity of some papaverine analogs. II
AU Sheikova, Zh.; Nikolova, M
SO Izvestiya na Instituta po Fiziologiya, Bulgarska Akademiya na Naukite (1964), 7, 243-52
CODEN: IIFBA4; ISSN: 0068-3922
DT Journal
LA Bulgarian
AB cf. CA 60, 14672h. The spasmolytic activity of the nicotinoyl, isonicotinoyl, and furanoyl derivs. were lower than papaverine (I). The o-methoxyphenol and trimethoxyphenol derivs. had equal or superior spasmolytic effects. The nonhydrated compds. of these derivs. had a depressive effect on the central nervous system, while the hydrated compds. had a stimulant effect. All compds., except those containing furanoyl and o-methoxyphenyl groups were less toxic than I.
IT 33033-84-0, Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-1-(3,4,5-trimethoxyphenyl)-
(antispasmodic activity of)
RN 33033-84-0 CAPLUS

CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-1-(3,4,5-trimethoxyphenyl)-
(CA INDEX NAME)



L5 ANSWER 60 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1965:93560 CAPLUS Full-text
DN 62:93560
OREF 62:16783e-g
TI Relations between chemical structure and pharmacological actions in a series of γ-lactones and amino alcohols
AU Zavrazhnov, V. I.; Ponomarev, F. G.; Trukhacheva, L. I.
CS Med. Inst., Voronezh
SO Elektron. i Khim. v Kardiol., Voronezhsk. Obl. Obshchestvo Kardiologov, Voronezhsk. Obl. Obshchestvo Terapevtov (1964) 348-58
DT Journal
LA Russian
AB The effects were investigated of synthetic derivs. of α-aceto-γ-butyrolactone (I), Et acetoacetate, morpholine (II) derivs., and derivs. of diethylaminopropanediol ether (III) on perfused blood vessels of frog's hind limb and of isolated rabbit ear, on rabbit intestinal strips in vitro, and on rabbit blood pressure. The L.D.100 was determined in mice. The introduction of Me and vinyl groups in the β-position or in both β- and γ-positions of I caused a reversal of its pharmacol. properties: the derivs. have a spasmolytic activity on blood vessels without any influence on systemic blood pressure and intestinal smooth muscle. Methylation in the β-position or in both β- and γ-positions enhanced the vasopressor activity of I. The introduction of MeOCH2, PrOCH2, and iso-PrOCH2 groups into I in the γ-position caused an increase of pressor properties; substitution of the propoxy group in the γ-position with Cl decreased the pressor activity of the compound and toxicity but had a neg. influence on intestinal peristaltic movements. Substitution of H. in the NH group of II derivs. by aliphatic groups caused an increase of pressor properties and toxicity. From 7 derivs. of III the most active ones were benzyl and Et derivs. which decreased rabbit blood pressure and caused a constriction of ear and limb blood vessels. All III derivs. inhibited the movements and tonus of the rabbit intestine.
IT 33033-84-0, Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-1-(3,4,5-trimethoxyphenyl)- (antispasmodic activity of)
RN 33033-84-0 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-1-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



L5 ANSWER 61 OF 61 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1955:84276 CAPLUS Full-text
DN 49:84276
OREF 49:15902h-i,15903a-i
TI Chemistry of vanillin and its derivatives. VI. Effective spasmolytic 1-phenylisoquinolines and diphenethylamines containing the guaiacyl grouping
AU Kratzl, K.; Horejschi, T.; Billek, G.
CS Univ. Vienna
SO Monatshefte fuer Chemie (1954), 85, 1154-65
CODEN: MOCMB7; ISSN: 0026-9247
DT Journal
LA Unavailable
OS CASREACT 49:84276
AB cf. C.A. 48, 1363g. Several 1-phenylisoquinolines were prepared from 4-(2-aminoethyl)guaiacol (I) and its benzyl ether (II), by forming amides, treating these with POCl3, and dehydrogenating. The following amides were prepared by treatment with the corresponding acyl or alkyl chloride (starting material, yield, and m.p. given): BzNHCH2CH2C6H3(OH)OMe-4,3, I, 94, 127°; BzNHCH2CH2C6H3(OBz)OMe-4,3 (III), I, -, -; BzNHCH2CH2C6H3(OCH2Ph)OMe-4,3 (IV), I (or II), 76, 134°; 3,4-MeO(AcO)C6H3CONHCH2CH2C6H3(OH)OMe-4,3, I, 89, 117-20°; 3,4-MeO-(BzO)C6H3CONHCH2CH2C6H3(OH)OMe-4,3 (V), I, 95, 133-6°; 3,4-MeO(PhCH2O)C6H3CONHCH2CH2C6H3(OH)OMe-4,3 (VI), I, 93, 146-7°; 3,4-MeO(BzO)C6H3CONHCH2CH2C6H3(OBz)OMe-4,3, V, 87, 154-5°; 3,4-MeO(PhCH2O)C6H3CONHCH2CH2C6H3(OBz)OMe-4,3, VI, 90, 143°; 3,4-MeO(PhCH2O)C6H3CONHCH2CH2C6H3(OCH2Ph)OMe-4,3 (VII), IV or II, 75-89, 167°; and 3,5,4-(MeO)2(PhCH2)OC6H3CONHCH2CH2C6H3(OCH2Ph)OMe-4,3 (VIII), II, 67, 125°. For the ring-closure, 5 millimoles of the amide was treated with 12.5 millimoles POCl3 in 60 ml. absolute xylene or PhMe at reflux for 20-60 min. The product was precipitated as a resinous mass by addition of petr. ether. The free base could be precipitated from dilute HCl solution (containing EtOH if necessary) by NH3 and recrystd. from EtOH-H2O. The hydrochloride could be recovered instead by excess concentrated HCl. The picrate was prepared from the free base with picric acid or from the hydrochloride with sodium picrate. In this way were made the following 3,4-dihydroisoquinolines and derivs. (substituents, starting compound, % yield, m.p. given): 7-benzoyloxy-6-methoxy-1-phenyl (IX), III, 78, 191-2° (picrate, m. 210-12°; hydrochloride, m. 209-12°); 7-benzyloxy-6-methoxy-1-phenyl, IV, 88, 137° (hydrochloride, m. 199°); 7-benzyloxy-1-(4-benzyloxy-3- methoxyphenyl)-6-methoxy (X), VII, 79, - (picrate, m. 203°); 7-benzyloxy-1-(4-benzyloxy-3,5-dimethoxyphenyl)-6-methoxy (XI), VIII, 77, - (picrate, m. 232°). Hydrolysis of IX with aqueous EtOH-NaOH gave 93% 6-methoxy-1-phenyl-3,4-dihydro-7-isoquinolinol, m. 180° (picrate, m. 240°; hydrochloride, m. 210-12°). Treatment of X with 20% HCl and recrystn. from dilute HCl gave 93% 1-(4-hydroxy-3-methoxyphenyl)-6-methoxy-3,4-dihydro-7-isoquinolinol hydrochloride (m. 258°). Similarly, XI gave 92% 1-(4-hydroxy-3,5-dimethoxyphenyl)-6-methoxy-3,4-dihydro-7-isoquinolinol hydrochloride (m.

234°, with 1 mol. H2O). The free bases (XII and XIII) could be obtained with K2CO3. Hydrogenation and recrystallization from EtOH or dilute HCl gave from XII 94% 1-(4-hydroxy-3-methoxyphenyl)-6-methoxy-1,2,3,4-tetrahydro-7-isoquinolinol hydrochloride (m. 182°), and from XIII 92% 1-(4-hydroxy-3,5-dimethoxyphenyl)-6-methoxy-1,2,3,4-tetrahydro-7- isoquinolinol hydrochloride (m. 150°, with 1 mol. H2O). The free bases (XIV and XV) were obtained by K2CO3 treatment. Pd dehydrogenation gave from XI 90% 7-benzoyloxy-6-methoxy-1-phenylisoquinoline (XVI) (oil); from XIV 50% 1-(4-hydroxy-3-methoxyphenyl)-6-methoxy-7-isoquinolinol (hydrochloride, from EtOH-2N HCl, m. 240°; picrate, m. 220°); and from XV 56% 1-(4-hydroxy-3,5-dimethoxyphenyl)-6-methoxy- 7-isoquinolinol (hydrochloride, from dilute HCl, m. 217°; picrate, m. 242-3°). Hydrolysis of XVI with aqueous EtOH-NaOH gave 75% 6-methoxy-1-phenyl-7-isoquinolinol (hydrochloride, m. 145-7°; picrate, m. 221-2°). 4-Benzyloxy-3,5-dimethoxybenzoic acid (XVII) (55.6%, m. 155-7° from EtOH-H2O) was prepared from 2 g. syringic acid with PhCH2Cl and KOH in EtOH. XVII formed 4-benzyloxy-3,5-dimethoxybenzoyl chloride (85%, m. 45°) with SOCl2 at 50-70°. Syringaldehyde (XVIII) (48%, m. 110-12°, from H2O) was prepared from 6.2 g. 5-methoxyprotocatechualdehyde with 12.6 g. Me2SO4 in 40 ml. H2O containing 9.3 g. NaOH, then acidification with HCl. XVIII sodium salt gave 62.5% 4,3,5-PhCH2O(MeO)2C6H3CHO (XIX) (m. 63° from EtOH) with PhCH2Cl in xylene. XIX (3.2 g.) in 25 ml. absolute EtOH with 0.8 g. MeNO2, 0.13 g. MeNH2.HCl, and 0.1 g. Na2CO3 was heated 24 hrs. at 40° to give 65% 4,3,5-PhCH2O (MeO)2, C6H3CH:CHNO2 (m. 133° from C6H6-EtOH). [3,4-MeO(PhCH2O)C6H3]2NH.HCl (XX) (m. 205-10° from EtOH) was prepared two ways: (A) 0.5 g. 3,4-MeO(PhCH2O)C6H3CH:CHNO2 was dissolved in 17 ml. HOAc plus 12 ml. C6H6. The solution was dropped into 50 mg. PtO2 in 3 ml. HOAc under H. After taking up 150 ml. H, the solution was filtered and evaporated to 20 ml. under reduced pressure. Addition of concentrated HCl precipitated 51% XX; (B) 1 g. 3,4-MeO(PhCH2O)C6H3CH2CH:NOH was dissolved in 35 ml. EtOH and added to 50 mg. PtO2 in 5 ml. EtOH under H. After absorption of 165 ml. H, XX (38%) was recovered as in A. XX (1 g.) was heated 3 hrs. at 130-40° with 14 ml. 38% formalin, the mixture was cooled and 2N HCl added to give 80% 4,4'-bisbenzyloxy-3,3'-dimethoxy-N-methyldiphenethylamine hydrochloride (m. 176-8°, from EtOH containing concentrated HCl; 1/2 mol. H2O of crystallization). XX (0.5 g.) on hydrolysis with 10 ml. concentrated HCl in 10 ml. EtOH gave 88% 4,4'-iminodiethylenediguaiacol hydrochloride (m. 205-8°, from concentrated HCl). All the isoquinolines, phenethylamines, and intermediates showed 1/5 to 1/20 the spasmolytic activity of papaverine.

IT 855737-16-5P, 7-Isoquinolinol, 1,2,3,4-tetrahydro-1-(4-hydroxy-3,5-dimethoxyphenyl)-6-methoxy-, hydrochloride 855737-18-7P, 7-Isoquinolinol, 1,2,3,4-tetrahydro-1-(4-hydroxy-3,5-dimethoxyphenyl)-6-methoxy-
RL: PREP (Preparation)
(preparation of)

RN 855737-16-5 CAPLUS

CN 7-Isoquinolinol, 1,2,3,4-tetrahydro-1-(4-hydroxy-3,5-dimethoxyphenyl)-6-methoxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 855737-18-7 CAPLUS
CN 7-Isoquinolinol, 1,2,3,4-tetrahydro-1-(4-hydroxy-3,5-dimethoxyphenyl)-6-methoxy- (CA INDEX NAME)



=> s l4 not l5
L6 14 L4 NOT L5

=> dis l6 1-14 bib abs fhitstr

L6 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:703811 CAPLUS Full-text
DN 147:118219
TI Preparation of isoquinoline aminopyrazole derivatives for the treatment of cancer
IN Chen, Li; Georges, Guy; Mertens, Alfred; Wu, Xihan
PA F. Hoffmann-La Roche AG, Switz.
SO PCT Int. Appl., 334pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007071348	A1	20070628	WO 2006-EP12112	20061215
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,				

CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US	20070179151	A1	20070802	US 2006-637733	20061212
US	7572809	B2	20090811		
AU	2006328997	A1	20070628	AU 2006-328997	20061215
CA	2633101	A1	20070628	CA 2006-2633101	20061215
EP	1966190	A1	20080910	EP 2006-840991	20061215
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP	2009519918	T	20090521	JP 2008-544887	20061215
NO	2008002643	A	20080901	NO 2008-2643	20080605
MX	2008007624	A	20080701	MX 2008-7624	20080612
ZA	2008005163	A	20090624	ZA 2008-5163	20080612
KR	2008076963	A	20080820	KR 2008-714869	20080619
CN	101341145	A	20090107	CN 2006-80048040	20080619
IN	2008CN03084	A	20090306	IN 2008-CN3084	20080619
PRAI EP	2005-27720	A	20051219		
WO	2006-EP12112	W	20061215		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 147:118219

GI



I



II

AB The title compds. I [R1 = H, alkyl, cycloalkyl; R2 = H or alkyl; R3 = (un)substituted alkyl, aryl, heteroaryl, etc.; R33 = H, alkyl or alkoxy; R4 = H, alkyl, alkoxy, etc.; R5 = H, alkyl, alkoxy, etc.; R6 = H, alkyl, alkoxy, etc. or R5 and R6 can form together with the carbon atoms to which they are attached a 5-6 membered heterocyclic ring; X = a bond, O, S, C(O), etc.], useful in the control or prevention of illnesses such as cancer, were prepared and formulated. E.g., a multi-step synthesis of II, starting from 1-indanone, was given. II showed IC50 of 0.066 μM against Aurora A kinase.

IT 942932-52-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of isoquinolinylamino pyrazoles for the treatment of cancer)

RN 942932-52-7 CAPLUS

CN 3-Isoquinolinamine, 1-(3,5-difluorophenyl)-6-methoxy-N-1H-pyrazol-3-yl- (CA INDEX NAME)



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:565283 CAPLUS Full-text
DN 146:528334
TI Novel colored solutions of injectable drugs and their salts
IN Winch, Peter D.
PA Winch, Peter, D., USA
SO PCT Int. Appl., 121 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007059019	A2	20070524	WO 2006-US43963	20061113
	WO 2007059019	A3	20080710		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	AU 2006315610	A1	20070524	AU 2006-315610	20061113
	CA 2635496	A1	20070524	CA 2006-2635496	20061113
	EP 1951248	A2	20080806	EP 2006-837427	20061113
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
	JP 2009515895	T	20090416	JP 2008-540243	20061113
	CN 101400369	A	20090401	CN 2006-80050729	20080709
	US 20090156562	A1	20090618	US 2008-93534	20081118
PRAI	US 2005-735370P	P	20051114		
	US 2005-736372P	P	20051114		
	US 2005-736373P	P	20051114		
	US 2005-736374P	P	20051114		
	US 2005-736464P	P	20051114		
	US 2005-736468P	P	20051114		
	US 2005-736573P	P	20051114		

US 2005-736574P	P	20051114
US 2005-736575P	P	20051114
US 2005-736576P	P	20051114
US 2005-736577P	P	20051114
US 2005-736578P	P	20051114
US 2005-736579P	P	20051114
US 2006-761274P	P	20060123
US 2006-761276P	P	20060123
US 2006-761277P	P	20060123
US 2006-761282P	P	20060123
US 2006-761283P	P	20060123
WO 2006-US43963	W	20061113

AB The invention is directed to pharmaceutical compns. comprising colored solns., colored emulsions, or colored powders of injectable pharmaceuticals wherein the pharmaceuticals are selected from the group consisting of muscle relaxants, hypnotics, induction agents, and anticholinergics. The formulations of the present invention may all be colored using fluorescein. Different colors may be achieved by either varying the concentration of fluorescein, or by combining fluorescein with another dye. The invention is also directed to methods involving the use of said pharmaceutical compns. A sterile aqueous solution contains atracurium besylate 10 mg/mL, and fluorescein (10 mg), wherein the pH of the solution is adjusted to 3.5 with benzenesulfonic acid.

IT 213998-46-0
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(colored solns. of injectable drugs and their salts)

RN 213998-46-0 CAPLUS

CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl−



L6 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:284437 CAPLUS Full-text
DN 146:337745
TI Preparation of tetrahydroisoquinoline derivatives as IGF-1 receptor inhibitors
IN Gunzinger, Jan; Leander, Kurt
PA Analytecon SA, Switz.
SO PCT Int. Appl., 52pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007029107	A1	20070315	WO 2006-IB2474	20060908
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	AU 2006288847	A1	20070315	AU 2006-288847	20060908
	CA 2621820	A1	20070315	CA 2006-2621820	20060908
	EP 1940796	A1	20080709	EP 2006-795449	20060908
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, RS				
	JP 2009507820	T	20090226	JP 2008-529711	20060908
	ZA 2008001910	A	20090826	ZA 2008-1910	20080229
	MX 2008003298	A	20080411	MX 2008-3298	20080307
	NO 2008001206	A	20080529	NO 2008-1206	20080307
	CN 101282935	A	20081008	CN 2006-80032919	20080307
	KR 2008065591	A	20080714	KR 2008-706725	20080320
	IN 2008DN02917	A	20080704	IN 2008-DN2917	20080408
	US 20090099133	A1	20090416	US 2008-991531	20080415
PRAI	US 2005-715170P	P	20050909		
	WO 2005-IB2667	A	20050909		
	WO 2006-IB2474	W	20060908		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS CASREACT 146:337745; MARPAT 146:337745

GI



I



II

AB The title compds. with general formula I [wherein R4 = H, OH, CN, CF3, etc.; R2 = H, Me, Et, etc.; R5 = H, alkyl, OH, etc.; R6 = Me, halo, alkoxy, etc.; n = 1-2; R7 and R8 = independently OH, Me, Et, methoxy, etc.; U = N or CR1, where R1 = H, alkyl, alkoxy, etc.; V = N or CR3, where R3 = H, OH, halo, etc.; W = N or CR9, where R9 = H, halo, CF3, etc.] or pharmaceutically acceptable salts thereof are prepared as inhibitors of IGF-1 receptor. For example, compound II and its prodrug, (1R)-1-(3,4,5-trimethoxyphenyl)-2-formyl-5-(dihydrogen phosphate)-6-methoxy-1,2,3,4-tetrahydroisoquinoline, were prepared from a multi-step synthesis. II showed IC50 values of 50 nM and 40 nM for the inhibition of phospho-MAPK (Erk1/2) and phospho-AKT, resp. I, as inhibitors of IGF-1R, are useful in the treatment of diseases such as but not limited to cancer, atherosclerosis, and psoriasis (no data).

IT 929050-66-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of tetrahydroisoquinoline derivs. as IGF-1 receptor inhibitors)

RN 929050-66-8 CAPLUS

CN 2(1H)-Isoquinolinecarboxaldehyde, 3,4-dihydro-5-hydroxy-6-methoxy-1-(3,4,5-trimethoxyphenyl)-, (1R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2007:64394 CAPLUS Full-text

DN 146:229193

TI Preparation of isoquinoline derivatives for treatment of tumor

IN Zhao, Yu; Ding, Hongxia; Lu, Wei
PA Zhejiang University, Peop. Rep. China
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 38 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CN 1896065	A	20070117	CN 2005-10082721	20050711
CN 101440096	A	20090527	CN 2008-10189046	20050711
CN 101440097	A	20090527	CN 2008-10189066	20050711
PRAI CN 2005-10082721	A3	20050711		

OS CASREACT 146:229193; MARPAT 146:229193
GI



I



II

AB The title 1-(3',4',5'-trisubstituted phenyl)isoquinoline derivs. I [R1-R3 = independently H, alkoxy, benzyloxy, hydroxy, halo, or amino; or R1 and R2 = -OCH2O- or -OCH2CH2O-; R4-R6 = independently alkoxy, benzyloxy, hydroxy, halo, or amino; or R4 and R5 or R5 and R6 = -OCH2O- or -OCH2CH2O-; R7 = absence, H, (un)substituted benzoyl, or cyclopropylcarbonyl; with provisos], or pharmaceutically acceptable salts, solvates, or mixts. thereof were prepared for the treatment of tumor (no data). For example, II was prepared in a multi-step synthesis. The compds. showed excellent antitumor activity.

IT 903527-19-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of isoquinoline derivs. for treatment of tumor)

RN 903527-19-5 CAPLUS
CN Isoquinoline, 1-[3,5-dimethoxy-4-(phenylmethoxy)phenyl]-1,2,3,4-tetrahydro-6,8-dimethoxy-7-(phenylmethoxy)- (CA INDEX NAME)



L6 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:1238764 CAPLUS Full-text
DN 146:229148
TI Synthesis and anticoagulant activity of 1-aryl derivatives of tetrahydroisoquinolines
AU Glushkov, V. A.; Arapov, K. A.; Minova, O. N.; Ismailova, N. G.; Syropyatov, B. Ya.; Shklyaev, Yu. V.
CS Perm State University, Perm, Russia
SO Pharmaceutical Chemistry Journal (2006), 40(7), 363-366
CODEN: PCJOAU; ISSN: 0091-150X
PB Springer
DT Journal
LA English
OS CASREACT 146:229148
GI



I

AB A series of 1-aryl-3,3-dimethyl-3,4-dihydroisoquinolines, e.g., I (R = H, Br, NO2 or MeO), were obtained by three-component (one-pot) condensation of veratrole, isobutylene oxide, and aromatic nitriles and then reduced to the corresponding 1,2,3,4-tetrahydroisoquinolines. Hydrochlorides of the synthesized compds. were tested for anticoagulant activity.

IT 924910-76-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and anticoagulant activity of aryl dihydro- and tetrahydroisoquinoline derivs. via three-component heterocyclization of veratrole with isobutylene oxide and aromatic nitriles followed by reduction with hydrides)

RN 924910-76-9 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-3,3-dimethyl-1-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:679649 CAPLUS Full-text
DN 146:287203
TI GW280430A (AV430A), a new ultrashort-acting nondepolarizing neuromuscular blockers
AU Xu, Ji-hong; Zheng, Si-ju
CS Department of Anesthesiology, General Hospital of Shenyang Command, Shenyang, 110016, Peop. Rep. China
SO Guowai Yixue Mazuixue Yu Fusu Fence (2005), 26(5), 295-297
CODEN: GYMYAS; ISSN: 1001-1005
PB Guowai Yixue Mazuixue Yu Fusu Fence Bianjibu
DT Journal; General Review
LA Chinese
AB A review. GW280430A had such characteristics as rapid effects, short action time, no accumulation and few bad responses, so it was the most promising non-depolarization muscle relaxing medicine which could replace succinylcholine. In this paper GW280430A (AV430A), a new ultrashort-acting nondepolarizing neuromuscular blockers is discussed.
IT 213998-46-0, GW280430A
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GW280430A (AV430A), new ultrashort-acting nondepolarizing neuromuscular blockers)
RN 213998-46-0 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl-



L6 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:1309229 CAPLUS Full-text
DN 144:304254
TI Muscle relaxants 2006: A clinical and basic science update and commentary
AU Lee, Chingmuh; Katz, Ronald L.
CS Department of Anesthesiology, Harbor-UCLA Medical Center, Torrance, CA, USA
SO Seminars in Anesthesia, Perioperative Medicine and Pain (2005), 24(3), 154-164
CODEN: SAPPFJ; ISSN: 1547-9951
PB Elsevier Inc.
DT Journal; General Review
LA English
AB A review. As muscle relaxants remain a mainstay of modern anesthesia practice, it behooves the anesthesiologists to keep themselves up-to-date on the theory and clin. practice of neuromuscular pharmacol. Progress continues to be made in the basic and clin. aspects of neuromuscular pharmacol., including mechanism of action, blocking drugs, and reversal agent. The new mechanism of action is based on the mol. shape of the relaxants. Although the so-called "ideal relaxant" is still not in sight, and may never be, the new relaxant AV430A and the new reversal agent Org 25969 hold potential to significantly improve patient care. AV430 has superior clin. profile, although it is still considerably slower and longer in action than succinylcholine. The fast onset of rocuronium combined with its complete and immediate reversibility with Org 25969 may match succinylcholine in onset and offset. Both drugs are undergoing clin. trials.
IT 213998-46-0, GW280430A
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(AV430A; AV430 has superior clin. profile but is slower in action than succinylcholine and fast onset of rocuronium combined with complete reversibility with reversal agent Org 25969 may match succinylcholine in onset and offset in patient)
RN 213998-46-0 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:1082676 CAPLUS Full-text
DN 145:188599
TI Synthesis and biological evaluation of novel compounds related to 1-arylnaphthalene lignans and isoquinolines
AU Ding, Hongxia; Lu, Wei; Li, Haibo; Yang, Leixiang; Zhang, Qijun; Zhou, Changxin; Wu, Xiumei; Baudoin, Olivier; Cai, Junchao; Gueritte, Francoise; Zhao, Yu
CS Department of Traditional Chinese Medicine and Natural Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310031, Peop. Rep. China
SO Chemistry & Biodiversity (2005), 2(9), 1217-1231
CODEN: CBHIAM; ISSN: 1612-1872
PB Verlag Helvetica Chimica Acta AG
DT Journal
LA English
OS CASREACT 145:188599
GI



I

AB Novel compds., e.g. I, designed as hybrids of 1-arylnaphthalene lignans with isoquinoline alkaloids were prepared and evaluated for their cytotoxicities on human tumor cell lines, such as A549, Hela, PC-3, CNE, BEL-7404, and KB. Some of the synthetic compds. exhibited their IC50 values on selected cell lines at 10-6 M scale. The preliminary CoMFA mol. modeling studies of these synthetic analogs were also performed.

IT 903527-19-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation and antitumor activity of arylnaphthalene lignan-isoquinoline hybrids)

RN 903527-19-5 CAPLUS

CN Isoquinoline, 1-[3,5-dimethoxy-4-(phenylmethoxy)phenyl]-1,2,3,4-tetrahydro-6,8-dimethoxy-7-(phenylmethoxy)- (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:1026936 CAPLUS Full-text
DN 143:326227
TI Preparation of tetrahydroisoquinoline and tetrahydrobenzazepine derivatives as IGF-1R inhibitors
IN Gunzinger, Jan; Leander, Kurt
PA Analytecon S. A., Switz.
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005087743	A1	20050922	WO 2004-CH147	20040312

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU	2004317166	A1	20050922	AU 2004-317166	20040312
CA	2555745	A1	20050922	CA 2004-2555745	20040312
EP	1732898	A1	20061220	EP 2004-719900	20040312
EP	1732898	B1	20080123		

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, LT, LV, MK

CN	1922147	A	20070228	CN 2004-80042030	20040312
BR	2004018462	A	20070605	BR 2004-18462	20040312
JP	2007528877	T	20071018	JP 2007-502162	20040312
AT	384700	T	20080215	AT 2004-719900	20040312
ES	2299825	T3	20080601	ES 2004-719900	20040312
NO	20060037794	A	20061212	NO 2006-3794	20060824
US	20070129399	A1	20070607	US 2006-591174	20060830
MX	2006010410	A	20061110	MX 2006-10410	20060912
IN	2006DN05643	A	20070831	IN 2006-DN5643	20060927

PRAI WO 2004-CH147 A 20040312

OS CASREACT 143:326227; MARPAT 143:326227

GI



I



II

AB Title compds. I [R2 = H, Me, Et, etc.; R5 = H, alkyl, OH, etc.; R6 = Me, alkoxy, OCF3, etc.; n = 1-2; R3 and R4 independently = OH, OMe, halo, etc.; U = N or CR1; R1 = H, alkyl, alkoxy, etc.; V = N or CR7; R7 = H, OH, halo, etc.; W = N or CR8; R8 = H, alkyl, alkoxy, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of IGF-1R. Thus, e.g., II was prepared by amidation of 3-methoxyphenylethylamine with 3,5-dichlorobenzoyl chloride followed by cyclization with POCl3 and subsequent reduction to the resp. secondary amine which was then acetylated. The

activity of I was evaluated in a cell growth inhibition study using human cell lines MCF-7 and SK-MEL 28 and it was revealed that compds. of the invention possessed IC50 values in the range of 8 μg/mL up to 150 pg/mL in at least one cell line. I as inhibitors of IGF-1R should prove useful in the treatment of diseases such as but not limited to cancer, atherosclerosis and psoriasis. Pharmaceutical compns. comprising I are disclosed.

IT 865151-32-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of tetrahydroisoquinoline and tetrahydrobenzazepine derivs. as IGF-1R inhibitors)

RN 865151-32-2 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-6-methoxy-1-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:715613 CAPLUS Full-text
DN 143:431761
TI Muscle relaxants
AU Takeda, Junzo
CS School of Medicine, Keio University, Japan
SO Sentan Iryo Shirizu (2005), 33(Masuika no Atarashii Nagare), 70-73
CODEN: SISEBJ
PB Sentan Iryo Gijutsu Kenkyusho
DT Journal; General Review
LA Japanese
AB A review, discussing the action mechanism, pharmacokinetics, and pharmacol. of new muscle relaxants, including rocuronium bromide, GW280430A, and TAAC3.
IT 213998-46-6, GW280430A
RL: DMA (Drug mechanism of action); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(action mechanism, pharmacokinetics, and pharmacol. of new muscle relaxants, including rocuronium bromide, GW280430A, and TAAC3)
RN 213998-46-6 CAPLUS
CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl−

PAGE 1-B



L6 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:540969 CAPLUS Full-text
DN 144:390714
TI Identification of novel anthrax lethal factor inhibitors generated by combinatorial Pictet-Spengler reaction followed by screening in situ
AU Numa, Mehdi M. D.; Lee, Lac V.; Hsu, Che-Chang; Bower, Kristen E.; Wong, Chi-Huey
CS Department of Chemistry and the Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA
SO ChemBioChem (2005), 6(6), 1002-1006
CODEN: CBCHFX; ISSN: 1439-4227
PB Wiley-VCH Verlag GmbH & Co. KGaA
DT Journal
LA English
OS CASREACT 144:390714
GI



I



II

AB Anthrax lethal factor (LF) is a zinc-dependent metalloprotease involved in the rapid development of the deadly infection caused by Bacillus anthracis. Blocking its action is a plausible method to mitigate the deleterious effects of late stage infection. We report the inhibition of LF by tetrahydro-isoquinoline poly phenolic compds. (I) (R = H, COMe, CH(SH)CH2OH, 2-cyclohexen-1-yl, 2-methylpropyl, n-heptyl, iso-Pr, chloromethyl, etc.), in particular (II), which were identified by screening a combinatorial library of 69 compds. that was generated by Pictet-Spengler reaction of 5-hydroxydopamine hydrochloride with aldehydes or ketones. II inhibited LF with Ki of 1.8 μM under physiol. salt concentration We also report the identification of com. available polyphenolic inhibitors against LF, e.g., Anthracene Brown G, Resorcin blue, tannic acid, and 1,2,3,4,6-penta-O-galloyl-β-D-glucopyranose.

IT 881426-40-0P
RL: BSU (Biological study, unclassified); CPN (Combinatorial preparation); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation)
(identification of anthrax lethal factor inhibitors generated by combinatorial Pictet-Spengler reaction of hydroxydopamine with aldehydes or ketones followed by screening in situ)

RN 881426-40-0 CAPLUS

CN 6,7,8-Isoquinolinetriol, 1-(3,5-dibromo-4-hydroxyphenyl)-1,2,3,4-tetrahydro- (CA INDEX NAME)



OSC.G 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)
RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:409312 CAPLUS Full-text
DN 142:441893
TI Neuromuscular blocking agents and antagonists thereof
IN Savarese, John J.
PA Cornell Research Foundation, Inc., USA
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	WO 2005041960	A2	20050512	WO 2004-US35869	20041028
	WO 2005041960	A3	20050707		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20050192243	A1	20050901	US 2004-975197	20041028
	EP 1684753	A2	20060802	EP 2004-810087	20041028
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI	US 2003-515048P	P	20031028		
	WO 2004-US35869	W	20041028		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 142:441893

AB The invention provides methods, compns. and kits for controlling the maximum clin. duration of an ultrashort to intermediate halofumarate neuromuscular blockers. In one embodiment, the methods of the invention involve fast-acting agents that antagonize the neuromuscular blockade caused by administration of a halofumarate neuromuscular blocking agent. Agents that can antagonize the neuromuscular blockade caused by administration of a halofumarate neuromuscular blocking agent include cysteine, N-acetylcysteine, glutathione, as well as related cysteine analogs and combinations thereof.

IT 213998-46-0, GW 280430A

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(halofumarate neuromuscular blocking agents and antagonists thereof such as cysteine analogs)

RN 213998-46-0 CAPLUS

CN Isoquinolinium, 2-[3-[[(2Z)-2-chloro-1,4-dioxo-4-[3-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)isoquinolinio]propoxy]-2-butenyl]oxy]propyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, chloride (1:2), (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



●2 Cl-

PAGE 1-B



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L6 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:284144 CAPLUS Full-text
DN 142:355176
TI Preparation of 6,8-dimethoxyisoquinolines as novel potassium channels modulators
IN Garcia, Gabriel; Saeb, Wael; Kramer, Bernd
PA 4SC AG, Germany
SO U.S. Pat. Appl. Publ., 54 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20050070570	A1	20050331	US 2004-869914	20040618
PRAI US 2003-479159P	P	20030618		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 142:355176
GI



I II

AB The invention relates to compds. I [Z = carbonyl, thiocarbonyl or sulfonyl; R1 = alkyl, alkenyl, alkynyl, aryl, H, halo, etc.; R2 = H, OH, CH2SO2alkyl, CH2SO2cycloalkyl, etc.; R5 = alkyl, alkenyl or alkynyl] which are useful for the prevention, alleviation or treatment of diseases, conditions or disorders which are associated with, or dependent on the membrane potential or conductance of cells in mammals, including a human. The general methods for synthesis of compds. I are described. One hundred sixty five compds. I (such as II) were prepared Biol. data were given for representative compds. I. The pharmaceutical composition comprising the compound I is claimed.

IT 848901-37-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 6,8-dimethoxyisoquinolines as novel potassium channels modulators)

RN 848901-37-1 CAPLUS

CN 2(1H)-Isoquinolinecarboxamide, N-(4-acetylphenyl)-1-(3,5-dichlorophenyl)-3,4-dihydro-6,8-dimethoxy- (CA INDEX NAME)



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L6 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2005:99335 CAPLUS Full-text

DN 142:198067

TI Preparation of pyrazolo[3,4-c]isoquinoline derivatives as anaplastic lymphoma kinase modulators

IN Anand, Neel Kumar; Blazey, Charles M.; Bowles, Owen Joseph; Bussenius, Joerg; Costanzo, Simona; Curtis, Jeffry Kimo; Dubenko, Larisa; Kennedy, Abigail R.; Khoury, Richard G.; Kim, Angie I.; Manalo, Jean-Claire L.; Peto, Csaba J.; Rice, Kenneth D.; Tsang, Tsze H.

PA Exelixis, Inc., USA

SO PCT Int. Appl., 239 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

PI	WO 2005009389	A2	20050203	WO 2004-US23762	20040723
	WO 2005009389	A3	20050915		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004259012	A1	20050203	AU 2004-259012	20040723
	CA 2532800	A1	20050203	CA 2004-2532800	20040723
	EP 1648455	A2	20060426	EP 2004-779018	20040723
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	JP 2006528638	T	20061221	JP 2006-521273	20040723
	US 20070032515	A1	20070208	US 2006-565657	20061005
PRAI	US 2003-489658P	P	20030723		
	WO 2004-US23762	W	20040723		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 142:198067; MARPAT 142:198067

GI



I



II

AB The title compds. I [wherein A = (hetero)cycle; R1-R3 = independently H, halo, CN, etc.; X1 and X2 = independently N or (un)substituted CH; X3 = O, S, or (un)substituted NH; n = 1-5; Y = N or (un)substituted CH] or pharmaceutically acceptable salts, stereoisomers, prodrugs, or metabolites thereof are prepared as inhibitors of anaplastic lymphoma kinase (ALK). For example, the compound II was prepared in a multi-step synthesis. Some of compds. I inhibited ALK with IC50 of ≤ 99 nM. I are useful for the treatment of diseases mediated by ALK, including diseases such as cancer, immunol. disorders, cardiovascular diseases, and other degenerative disorders (no data). Formulations containing I as an active ingredient were also described.

IT 838854-82-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrazolo[3,4-c]isoquinoline derivs. as anaplastic lymphoma kinase modulators)

RN 838854-82-3 CAPLUS

CN Phenol, 4-(7,8-dimethoxy-1-methyl-3H-pyrazolo[3,4-c]isoquinolin-5-yl)-2,6-

dimethoxy- (CA INDEX NAME)



OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y
STN INTERNATIONAL LOGOFF AT 09:36:11 ON 14 DEC 2009